

CURRICULUM VITAE

CAITLIN C. MURPHY, PhD, MPH, CPH

Associate Professor

Center for Health Promotion and Prevention Research

Department of Health Promotion and Behavioral Sciences

University of Texas Health Science Center at Houston (UTHealth Houston)

7000 Fannin Street, Suite 2618

Houston, TX 77030

Tel: (713) 500-9105

Fax: (713) 500-9602

caitlin.c.murphy@uth.tmc.edu

Education

College of Arts and Sciences, New York University, New York, NY

Bachelor of Arts (BA), Sociology, *Magna Cum Laude*, 2010

UTHealth Houston School of Public Health, Houston, TX

Master of Public Health (MPH), Health Promotion and Behavioral Science, 2011

Advisor: Sally W. Vernon, PhD

Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC

Doctor of Philosophy (PhD), Epidemiology, 2016

Advisor/Dissertation Committee Chair: Robert S. Sandler, MD, MPH

Dissertation: "Examining the increasing incidence of colorectal cancer in younger adults"

Licensure and Certification

Certified in Public Health (CPH)

National Board of Public Health Examiners, 2011

Certification# NBPHE-IND-6749

Positions and Employment

2010—2011 *Research Coordinator*, Institute for Cancer Care Excellence, University of Texas M.D. Anderson Cancer Center, Houston, TX

2011 *Senior Research Coordinator*, Institute for Cancer Care Excellence, University of Texas M.D. Anderson Cancer Center, Houston, TX

2011—2013 *Project Director*, Center for Health Promotion and Prevention Research, UTHealth Houston School of Public Health, Houston, TX

2013—2016 *Predoctoral Fellow*, Digestive Disease Epidemiology Training Program, University of North Carolina at Chapel Hill, Chapel Hill, NC

2016—2021 *Assistant Professor*, Division of Epidemiology, Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX

- 2016—2019 *Associate Member, Population Sciences & Cancer Control Program, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX*
- 2017—2021 *Adjunct Assistant Professor, UTHealth School of Public Health, Dallas Regional Campus, Dallas, TX*
- 2018—2021 *Assistant Professor (secondary appointment), Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX*
- 2019—2021 *Member, Population Sciences & Cancer Control Program, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX*
- 2021—present *Associate Professor, Department of Health Promotion and Behavioral Sciences, UTHealth Houston School of Public Health, Houston, TX*
- 2021—present *Associate Professor (secondary appointment), Department of Epidemiology, Human Genetics, and Environmental Sciences, UTHealth Houston School of Public Health, Houston, TX*
- 2021—present *Member, Center for Health Promotion and Prevention Research, UTHealth Houston School of Public Health, Houston, TX*
- 2021—present *Adjunct Associate Professor, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX*

Other Experience and Professional Memberships

- 2010—present *Member, Phi Beta Kappa*
- 2013—present *Member, Society for Epidemiologic Research*
- Summer 2014 *Research Volunteer, Health Services and Economics Branch, Applied Research Program, National Cancer Institute, Rockville, MD*
- Summer 2015 *Research Volunteer, Healthcare Assessment Research Branch, Healthcare Delivery Research Program, National Cancer Institute, Rockville, MD*
- 2019—present *Member, American Gastroenterological Association*
- 2019—present *Member, Medical Advisory Board, Fight Colorectal Cancer*
- 2020—2021 *Member, Colorectal Cancer Screening Panel, National Comprehensive Cancer Network*
- 2021—present *Member, Executive Committee, Screening Continuum Task Force, American Gastroenterological Association*
- 2021—present *Member, Advisory Committee to the Texas Cancer Registry*
- 2022—present *Vice Chair, Advisory Committee to the Texas Cancer Registry*

Honors and Awards

- 2010 Faculty Prize Award for Outstanding Graduating Seniors, New York University

- 2010 Presidential Honors Scholar, New York University
- 2010 Founders Day Award for Outstanding Scholastic Achievement, New York University
- 2010 Phi Beta Kappa, Beta Chapter of New York
- 2011 State of Texas Merit Grant Recipient, University of Texas School of Public Health
- 2013 Promise of One Award, Houston Affiliate of Susan G. Komen for the Cure
- 2016 Delta Omega, Theta Chapter at the University of North Carolina at Chapel Hill
- 2017 AcademyHealth New Investigator Award
- 2017 Clinical Research Scholar, University of Texas Southwestern Medical Center

Publications in Peer-Reviewed Journals

** indicates role as faculty mentor*

1. **Murphy CC**, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. *Breast Cancer Res Treat* 2012; 134(2):459-78. Epub 2012 Jun 12. doi:10.1007/s10549-012-2114-5. PMID: 22689091. PMCID: PMC3607286.
2. **Murphy CC**, Hofstetter WL, Correa AM, Ajani JA, Komaki RU, Swisher SG. Utilization of surgery in trimodality eligible patients with locally advanced esophageal adenocarcinoma in a non-protocol setting. *Dis Esophagus* 2013; 26(7):708-15. Epub 2013 Jan 25. doi: 10.1111/dote.12019. PMID: 23350713.
3. Carpentier MY, Vernon SW, Bartholomew LK, **Murphy CC**, Bluethmann SM. Receipt of recommended surveillance guidelines among colorectal cancer survivors: a systematic review. *J Cancer Survivor* 2013; 7(3): 464-83. Epub 2013 May 16. doi: 10.1007/s11764-013-0290-x. PMID: 23677524. PMCID: PMC3737369.
4. **Murphy CC**, Correa AM, Ajani JA, Komaki RU, Welsh JW, Swisher SG, Hofstetter WL. Surgery is an essential component of multimodality therapy for locally advanced esophageal adenocarcinoma. *J Gastrointest Surg* 2013; 17(8):1359-69. Epub 2013 May 29. doi: 10.1007/s11605-013-2223-4. PMID: 23715646. PMCID: PMC4998180.
5. **Murphy CC**, Incalcaterra JR, Albright HW, Correa AM, Swisher SG, Hofstetter WL. Pretreatment patient comorbidity and tobacco use increases cost and risk of postoperative complications following esophagectomy at a high volume cancer center. *J Oncol Pract* 2013; 9(5):233-9. Epub 2013 July 29. doi: 10.1200/jop.2013.001047. PMID: 23943906.
6. **Murphy CC**, McQueen A, Bartholomew LK, Del Junco DJ, Coan SP, Vernon SW. Factorial validity and invariance of four psychosocial constructs of colorectal cancer screening: does screening experience matter? *Cancer Epidemiol Biomarkers Prev* 2013; 22(12):2295-302. Epub 2013 Sept 20. doi: 10.1158/1055-9965. PMID: 24057575. PMCID: PMC3858498.
7. **Murphy CC**, Vernon SW, Diamond PM, Tiro JA. Competitive testing of health behavior theories: how do benefits, barriers, subjective norm, and intention influence mammography behavior? *Ann Behav Med* 2014; 47:120-9. Epub 2013 July 19. doi: 10.1007/s12160-013-9528-0. PMID: 23868613. PMCID: PMC3941986.
8. **Murphy CC**, Vernon SW, Haddock NM, Anderson ML, Chubak J, Green BB. Longitudinal

predictors of colorectal cancer screening among participants in a randomized controlled trial. *Prev Med* 2014; 66:123-30. Epub 2014 June 15. doi: 10.1016/j.ypmed.2014.06.013. PMID: 24937648. PMCID: PMC4209306.

9. **Murphy CC**, Lewis CL, Golin CE, Sandler RS. Underuse of surveillance colonoscopy in patients at increased risk of colorectal cancer. *Am J Gastroenterol* 2015; 110(5):633-41. Epub 2014 Nov 12. doi: 10.1038/ajg.2014.344. PMID: 25384901. PMCID: PMC4422764.
10. **Murphy CC**, Martin CF, Sandler RS. Racial differences in obesity measures and risk of colorectal adenomas in a large screening population. *Nutr Cancer* 2015; 67(1):98-104. Epub 2014 Nov 25. doi: 10.1080/01635581.2015.976316. PMID: 25425186. PMCID: PMC4281505.
11. Bluethmann SM, Vernon SW, Gabriel KP, **Murphy CC**, Bartholomew LK. Taking the next step: a systematic review and meta-analysis of physical activity interventions and behavior change interventions in post-treatment breast cancer survivors. *Breast Cancer Res Treat* 2015; 149(2):331-42. Epub 2015 Jan 3. doi: 10.1007/s10549-014-3255-5. PMID: 25555831. PMCID: PMC4310805.
12. Tiro JA, Sanders J, Shay LA, **Murphy CC**, Hamann H, Bartholomew LK, Carpentier MY, Vernon SW. Validation of self-reported post-treatment mammography surveillance among breast cancer survivors. *Breast Cancer Res Treat* 2015; 151(2):427-34. Epub 2015 Apr 29. doi:10.1007/s10549-015-3387-2. PMID: 25922083. PMCID: PMC4935542.
13. **Murphy CC**, Harlan LC, Warren JL, Geiger AM. Race and insurance differences in the receipt of adjuvant chemotherapy among stage III colon cancer patients. *J Clin Oncol* 2015; 33(23):2530-6. Epub 2015 July 6. doi: 10.1200/JCO.2015.61.3026. PMID: 26150445. PMCID: PMC4525047.
14. **Murphy CC**, Harlan LC, Lund JL, Lynch CF, Geiger AM. Patterns of colorectal cancer care in the United States: 1990-2010. *J Natl Cancer Inst* 2015; 107(10): pii: djv198. Epub 2015 July 23. doi: 10.1093/jnci/djv198. PMID: 26206950. PMCID: PMC4840367.
15. **Murphy CC**, Sandler RS, Grubber JM, Johnson MR, Fisher DA. Underuse and overuse of colonoscopy for screening and surveillance in the Veterans Health Administration. *Clin Gastroenterol Hepatol* 2016; 14(3):436-44. Epub 2015 Oct 19. doi: 10.1016/j.cgh.2015.10.008. PMID: 26492843. PMCID: PMC4761454.
16. Bluethmann SM, **Murphy CC**, Bartholomew LK, Vernon SW. Use of theory in behavior change interventions: an analysis of programs to increase physical activity in post-treatment breast cancer survivors. *Health Educ Behav* 2017; 44(2):245-53. Epub 2016 May 25. doi: 10.1177/1090198116647712. PMID: 27226430. PMCID: PMC5503486.
17. **Murphy CC**, Sandler RS, Sanoff HK, Yang YC, Lund JL, Baron JA. Decrease in incidence of colorectal cancer among individuals 50 years or older following recommendations for population-based screening. *Clin Gastroenterol Hepatol* 2017; 15(6):903-9. Epub 2016 Sept 5. doi: 10.1016/j.cgh.2016.08.037. PMID: 27609707. PMCID: PMC5337450.

Invited commentary by: Kahi CJ. A colorectal cancer moonshot. *Clin Gastroenterol Hepatol* 2017; 15(6):910-12. Epub 2017 Jan 18. doi: 10.1016/j.cgh.2017.01.00. PMID: 28110096.

18. Atiq O, Tiro J, Yopp AC, Muffler A, Marrero JA, Parikh ND, **Murphy C**, McCallister K, Singal AG. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. *Hepatology* 2017; 65(4):1196-1205. Epub 2016 Oct 24. doi: 10.1002/hep/28895. PMID: 27775821. PMCID: PMC5659110.
19. **Murphy CC**, Yang YC, Shaheen NJ, Hofstetter WL, Sandler RS. An age-period-cohort analysis of obesity and incident esophageal adenocarcinoma among white males. *Dis Esophagus* 2017; 30(3):1-8. Epub 2016 Nov 9. doi: 10.1111/dote.12526. PMID: 27862652. PMCID: PMC5386785.
20. **Murphy CC**, Sanoff HK, Stitzenberg KB, Lund JL, Baron JA, Sandler RS. Patterns of sociodemographic and clinicopathologic characteristics of stages II and III colorectal cancer patients by age: examining potential mechanisms of young-onset disease. *J Cancer Epidemiol* 2017; 2017:4024580. Epub 2017 Jan 23. doi: 10.1155/2017/4024580. PMID: 28239395. PMCID: PMC6440264.
21. **Murphy CC**, Tiro JA, Jean GW, Balasubramanian B, Alvarez CA. High initiation of adjuvant hormonal therapy among uninsured stages I-III breast cancer patients treated in a safety-net system. *J Womens Health (Larchmt)* 2017; 26(6):655-61. Epub 2017 March 15. doi: 10.1089/jwh.2016.609. PMID: 28296574. PMCID: PMC5512308.
22. **Murphy CC**, Lund JL, Sandler RS. Young-onset colorectal cancer: earlier diagnoses or increasing disease burden? *Gastroenterology* 2017; 152(8):1809-12. Epub 2017 Apr 28. doi: 10.1053/j.gastro.2017.04.03. PMID: 28461196. PMCID: PMC5646667. **Featured on June 2017 cover*
23. Bluethmann SM, **Murphy CC**, Tiro JA, Vernon SW, Bartholomew LK. Deconstructing decisions to initiate, maintain or discontinue adjuvant hormonal therapy in breast cancer survivors: a mixed-methods study. *Oncol Nurs Forum* 2017; 44(3): E101-E110. Epub 2017 May 1. doi: 10.1188/17.ONF.E101-E110. PMID: 28635973. PMCID: PMC5507080.
24. Naveed M, Clary M, Ahn C, Kubiliun N, Agrawal D, Cryer B, **Murphy C**, Singal AG. Accuracy of referring provider and endoscopist impression of colonoscopy indication. *J Natl Compr Canc Netw* 2017; 15(7):920-5. Epub 2017 July 1. doi: 10.6004/jnccn.2017.0123. PMID: 28687580.
25. Singal AG, Gupta S, Skinner CS, Ahn C, Santini NO, Agrawal D, Mayorga CA, **Murphy C**, Tiro JA, McCallister K, Tiro JA, Sanders JM, Bishop WP, Loewen AC, Halm EA. Effect of colonoscopy outreach vs. fecal immunochemical test outreach on colorectal cancer screening completion: a randomized clinical trial. *JAMA* 2017; 318(9):806-15. Epub 2017 Sept 5. doi: 10.1001/jama.2017.1138. PMID: 28873161. PMCID: PMC5648645.
Invited commentary by: Pignone M, Miller DP. Using outreach to improve colorectal cancer screening. *JAMA* 2017; 318(9):799-800. doi: 10.1001/jama.2017.10606. PMID: 28873142.
26. Mokdad AA, **Murphy CC**, Pruitt SL, Mansour JC, Marrero JA, Singal AG, Yopp AC. Effect of hospital safety-net status on treatment use and outcomes in hepatocellular carcinoma. *Cancer* 2018; 124(4):743-51. Epub 2017 Oct 26. doi: 10.1002/cncr.31066. PMID: 29070773.
27. **Murphy CC**, Gerber DE, Pruitt SL. Prior cancer among persons newly diagnosed with cancer: an initial report from the Surveillance, Epidemiology, and End Results program. *JAMA Oncol* 2018; 4(6):832-6. Epub 2017 Nov 22. doi: 10.1001/jamaoncol.2017.3605. PMID: 29167866. PMCID: PMC6370034.

Invited commentary by: Davidson NE. Incident cancer in cancer survivors—when cancer lurks in the background. *JAMA Oncol* 2018; 4(6):836-7. Epub 2012 Nov 22. doi: 10.1001/jamaoncol.2017.4167. PMID: 29167860.

Selected media coverage: Jane E. Brody. When cancer strikes twice. *New York Times*. December 26, 2017:D5. https://www.nytimes.com/2017/12/25/well/when-cancer-strikes-twice.html?_r=0

28. **Murphy CC**, Sigel BM, Yang E, Skinner CS, Halm EA, Gupta S, Sanders JM, McCallister K, Singal AG. Proportion of time covered to measure adherence to colorectal cancer screening. *Gastrointest Endosc* 2018; 88(22):323-31. Epub 2018 Feb 22. doi: 10.1016/j.gie.2018.02.023. PMID: 29477302. PMCID: PMC6050149.

Invited commentary by: Anderson JC, Robertson DJ. Monitoring compliance with colorectal cancer screening: do we have it covered? *Gastrointest Endosc* 2018; 88(2):332-4. doi: 10.1016/j.gie.2018.04.011. PMID: 30012412.

29. **Murphy CC**, Fullington HM, Alvarez CA, Betts AC, Lee SJC, Haggstrom DA, Halm EA. Polypharmacy and patterns of prescription medication use among cancer survivors. *Cancer* 2018; 124(13):2850-7. Epub 2018 Apr 12. doi: 10.1002/cncr.31389. PMID: 29645083. PMCID: PMC6147245.
30. **Murphy CC**, Singal AG. Establishing a research agenda for early-onset colorectal cancer. *PLoS Med* 2018; 15(6):e1002577. doi: 10.1371/journal.pmed.1002577. PMID: 29856736. PMCID: PMC5983407.
- Selected media coverage:* "Rehabilitative Medicine." *Doctor Radio*. Sirius XM, 26 June 2018.
31. Rich NE, Hester C, Odewole M, **Murphy CC**, Parikh ND, Marrero JA, Yopp YC, Singal AG. Racial and ethnic differences in presentation and outcomes of hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2019; 17(3):551-9. Epub 2018 May 31. doi: 10.1016/j.cgh.2018.05.039. PMID: 29859983. PMCID: PMC6274621.
32. Singal AG, Tiro JA, **Murphy CC**, Marrero JA, McCallister K, Fullington H, Mejias C, Waljee AK, Bishop WP, Santini NO, Halm EA. Mailed outreach invitations significantly improve HCC screening rates in patients with cirrhosis: a randomized clinical trial. *Hepatology* 2019; 69(1):121-30. Epub 2018 Aug 2. doi: 10.1002/hep.30129. PMID: 30070379. PMCID: PMC6324997.
33. Liang P, Allison J, Ladabaum U, Martinez ME, **Murphy CC**, Schoen RE, Shaukat A, Tinmouth J, Gupta S. Potential intended and unintended consequences of recommending initiation of colorectal cancer screening at age 45 years. *Gastroenterology* 2018; 155(4): 950-4. Epub 2018 Aug 20. doi: 10.1053/j.gastro.2018.08.019. PMID: 30138614.
34. **Murphy CC**, Singal AG, Baron JA, Sandler RS. Decrease in incidence of young-onset colorectal cancer before recent increase. *Gastroenterology* 2018; 155(6):1716-19. Epub 2018 Aug 28. doi: 10.1053/j.gastro.2018.07.045. PMID: 30165046. PMCID: PMC6279567.
35. Garcia S, Pruitt SL, Singal AG, **Murphy CC***. Colorectal cancer incidence among Hispanics and non-Hispanic whites in the United States. *Cancer Cause Control* 2018; 29(11):1039-46. Epub 2018 Aug 28. doi: 10.1007/s10552-018-1077-1. PMID: 30155605. PMCID: PMC6628724.

36. Wheeler SB, Spencer JC, Pinheiro LC, **Murphy CC**, Earp J, Carey L, Olshan A, Tse J, Bell ME, Weinberger M, Reeder-Hayes KE. Endocrine therapy non-adherence and discontinuation in Black versus White women. *J Natl Cancer Inst* 2019; 111(5):498-508. Epub 2018 Sept 20. doi: 10.1093/jnci/djy136. PMID: 30239824. PMCID: PMC6510227.
37. Peery AF, Crockett SD, **Murphy CC**, Lund JL, Dellon ES, Williams JL, Jensen ET, Shaheen NJ, Barritt AS, Lieber SR, Kochar B, Barnes EL, Fan YC, Baron TH, Galanko J, Sandler RS. Burden and cost of gastrointestinal, liver and pancreatic diseases in the United States: Update 2018. *Gastroenterology* 2019; 156(1):254-72. Epub 2018 Oct 10. doi: 10.1053/j.gastro.2018.08.063. PMID: 30315778. PMCID: PMC6689327.
38. Magrath M, Yang E, Ahn C, Mayorga CA, Gopal P, **Murphy CC**, Gupta S, Agrawal D, Halm EA, Skinner CS, Singal AG. Impact of a clinical decision support system on guideline adherence of surveillance recommendations for colonoscopy after polypectomy. *J Natl Compr Canc Netw* 2018; 16(11):1321-38. doi: 10.6004/jnccn.2018.7050. PMID: 30442733. PMCID: PMC7210781.
39. **Murphy CC**, Ahn C, Pruitt SL, Hughes AE, Halm EA, Gupta S, Santini NO, McCallister K, Sanders JM, Singal AG, Skinner CS. Screening initiation with FIT or colonoscopy: post-hoc analysis of a pragmatic, randomized trial. *Prev Med* 2019; 118:332-5. Epub 2018 Nov 30. doi: 10.1016/j.ypmed.2018.11.020. PMID: 30508552. PMCID: PMC6362977.
40. **Murphy CC**, Wallace K, Sandler RS, Baron JA. Racial disparities in the incidence of young-onset colorectal cancer and patient survival. *Gastroenterology* 2019; 156(4):958-65. Epub 2018 Dec 3. doi: 10.1053/j.gastro.2018.11.060. PMID: 30521807. PMCID: PMC6409160. **Featured on March 2019 cover*
- Invited commentary by:* Martinez ME, Murphy JD, Gomez SL. Black-white disparities in young-onset colorectal cancer: understanding complexity in reported differences. *Gastroenterology* 2019. Epub 2019 Feb 15. doi: 10.1053/j.gastro.2019.02.01. PMID: 30776345.
41. Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld J, John B, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Modi A, Flores A, Satapathy S, Wong R, Huang A, Misra S, Schwartz M, Haste P, Mitrani R, Ho C, Sharma S, Dao A, Nelson K, Delarosa K, Rahim U, Mayuram M, Zie JJ, **Murphy CC**‡, Parikh ND‡. Direct-acting antiviral therapy is not associated with HCC recurrence: a multicenter North American cohort study. *Gastroenterology* 2019; 156(6):1683-92. Epub 2019 Jan 17. doi: 10.1053/j.gastro.2019.01.027. PMID: 30660729. PMCID: PMC6598433. ‡Co-senior authors
- Invited commentary by:* Nault J, Nahon P. Can we move on from the discussion of direct antiviral agents and risk of hepatocellular carcinoma recurrence? *Gastroenterology* 2019; 156(6):1558-60. Epub 2019 Mar 26. doi: 10.1053/j.gastro.2019.03.02 PMID: 30926345.
42. Rich NE, Singal AG, **Murphy CC***. Hepatocellular carcinoma incidence is decreasing among younger adults in the United States. *Clin Gastroenterol Hepatol* 2020; 18(1):242-8. Epub 2019

April 28. doi: 10.1016/j.cgh.2019.04.043. PMID: 31042582. PMCID: PMC6817412.

43. Tavakkoli A, Singal AG, Waljee AK, Scheiman JM, **Murphy CC**, Pruitt SL, Xuan L, Kwon RS, Law RJ, Elta GH, Wright-Slaughter P, Valley TS, Kubilius N, Nathan H, Rubenstein JH, Elmunzer BJ. Regional and racial variations in the utilization of endoscopic retrograde cholangiopancreatography among pancreatic cancer patients in the United States. *Cancer Med* 2019; 8(7):3420-7. Epub 2019 May 14. doi: 10.1002/cam4.2225. PMID: 31087545. PMCID: PMC6601581.
44. **Murphy CC** (invited by Robert Sandler, MD, MPH). Colorectal cancer in the young: does screening make sense? *Curr Gastroenterol Rep* 2019; 21(7):28. Epub 26 May 2019. doi: 10.1007/s11894-019-0695-4. PMID: 31098760. PMCID: PMC6657498.
45. Lee SJC, **Murphy CC**, Geiger AM, Gerber DE, Cox JV, Nair R, Skinner CS. A conceptual model for accrual to cancer clinical trials. *J Clin Oncol* 2019; 37(23):1993-6. Epub 2019 June 5. doi: 10.1200/JCO.19.00101. PMID: 31166822. PMCID: PMC6879309.
46. Tavakkoli A, Singal AG, Waljee AK, Elmunzer E, Pruitt SL, McKey T, Rubenstein JH, Scheiman JM, **Murphy CC***. Racial and geographic disparities in pancreatic cancer incidence and mortality in the United States. *Clin Gastroenterol Hepatol* 2020; 18(1):171-8. Epub 2019 June 13. doi: 10.1016/j.cgh.2019.05.059. PMID: 31202981. **Featured on January 2020 cover*
47. **Murphy CC**, Lee SJC, Gerber DE, Cox JO, Fullington HM, Higashi RT. Patient and provider perspectives on delivery of oral cancer therapies. *Patient Educ Couns* 2019; 102(11):2102-9. Epub 2019 June 20. doi: 10.1016/j.pec.2019.06.019. PMID: 31239181. PMCID: PMC6777994.
48. Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld J, John B, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Modi A, Flores A, Satapathy S, Wong R, Huang A, Misra S, Schwartz M, Haste P, Mitrani R, Ho C, Sharma S, Dao A, Nelson K, Delarosa K, Rahim U, Mayuram M, Zie JJ, Parikh ND‡, **Murphy CC‡**. Direct-acting antiviral therapy for HCV infection is associated with increased survival in patients with a history of hepatocellular carcinoma. *Gastroenterology* 2019; 157(5):1253-63. Epub 2019 July 30. doi: 10.1053/j.gastro.2019.07.040. PMID: 31374215. PMCID: PMC6815711. ‡Co-senior authors
49. Stoffel EM, **Murphy CC** (invited by John Inadomi, MD). Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults. *Gastroenterology* 2020; 18(1):171-8. Epub 2019 Aug 5. doi: 10.1053/j.gastro.2019.07.055. PMID: 31394082. PMCID: PMC6957715. **Featured on January 2020 cover*
50. Dharwadkar P, Greenan G, Singal AG, **Murphy CC***. Is colorectal cancer in patients younger than 50 years the same disease as in older patients? *Clin Gastroenterol Hepatol* 2021; 19(1):1920194. Epub 2019 Oct 25. doi: 10.1016/j.cgh.2019.10.028. PMID: 31669054.
51. **Murphy CC**, Sen A, Watson B, Gupta S, Mayo H, Singal AG. A systematic review of repeat fecal occult blood tests for colorectal cancer screening. *Cancer Epidemiol Biomarkers Prev* 2020; 29(2):278-87. Epub 2019 Nov 28. doi: 10.1158/1055-9965.EPI-19-077. PMID: 31740521.

PMCID: PMC7007334.

52. **Murphy CC**, Lee SJC, Geiger AM, Cox JV, Ahn C, Nair R, Gerber DE, Halm EA, McCallister K, Skinner CS. A randomized trial of mail and email recruitment strategies for a physician survey on clinical trial accrual. *BMC Med Res Method* 2020 (1):123. Epub 2020 May 19. doi: 10.1186/s12874-020-01014-x. PMID: 32429848. PMCID: PMC7236338.
53. **Murphy CC**, Skinner CS, Halm EA, Balasubramanian BA, Singal AG. Challenges and approaches to measuring repeat fecal immunochemical test for colorectal cancer screening. *Cancer Epidemiol Biomarkers Prev* 2020; 29(8):1557-1563. Epub 2020 May 26. doi: 10.1158/1055-9965.EPI-20-0230. PMID: 32457184. PMCID: PMC7416474.
54. Faqih A, Singal AG, Fullington HM, Hewitt B, Burstein E, Gopal P, Wylie A, Abrams J, **Murphy CC***. Colorectal neoplasia among patients with and without human immunodeficiency virus. *Cancer Epidemiol Biomarkers Prev* 2020; 29(8):1689-1691. Epub 2020 May 28. doi: 10.1158/1055-9965.EPI-20-0021. PMID: 32467350. PMCID: PMC7415639.
55. Chubak J, Anderson M, Jackson M, **Murphy CC**, Cook A, Green BB. Methodological considerations in calculating and analyzing proportion of time covered as a measure of longitudinal cancer screening adherence. *Cancer Epidemiol Biomarkers Prev* 2020; 29(8):1549-1556. Epub 2020 May 28. doi: 10.1158/1055-9965.EPI-20-0388. PMID: 32467346. PMCID: PMC7415680.
56. Tavakkoli A, Elmunzer BJ, Waljee AK, **Murphy CC**, Pruitt SL, Huang C, Zhu H, Rong R, Kwon RS, Scheiman JM, Rubenstein JH, Singal AG. Survival analysis among unresectable pancreatic adenocarcinoma patients undergoing endoscopic or percutaneous interventions. *Gastrointest Endosc* 2021; 93(1):154-162. Epub 2020 June 9. doi: 10.1016/j.gie.2020.05.061. PMID: 32531402. PMCID: PMC8786308.
57. Rich NE, **Murphy CC***, Yopp AC, Tiro JA, Marrero JA, Singal AG. Sex disparities in presentation and prognosis of 1,110 patients with hepatocellular carcinoma. *Aliment Pharmacol Ther* 2020; 52(4):701-709. Epub 2020 June 29. doi: 10.1111/apt.15917. PMID: 32598091. PMCID: PMC7655123.
58. Singal AG, Tiro JA, **Murphy CC**, Blackwell JM, Kramer JR, Khan A, Liu J, Zhang S, Phillips J, Hernaez J. Patient-reported barriers are associated with HCC surveillance receipt in a multi-center cohort of patients with cirrhosis. *Clin Gastroenterol Hepatol* 2021; 19(5):987-995. Epub 2020 Jul 3. doi: 10.1016/j.cgh.2020.06.049. PMID: 32629122. PMCID: PMC7779689.
59. Jetelina KK, Carr C, **Murphy CC**, Sadeghi N, Lea J, Tiro JA. The impact of intimate partner violence on breast and cervical cancer survivors in an integrated, safety-net setting. *J Cancer Surviv* 2020; 14(6):906-914. Epub 2020 Jul 15. doi: 10.1007/s11764-020-00902-x. PMID: 32671556.
60. Kolb JM, Han S, Scott FI, **Murphy CC**, Hosokawa P, Wani S. Early-onset esophageal adenocarcinoma presents with advanced stage disease but has improved survival compared with older individuals. *Gastroenterology* 2020; 159(6):2238-2240. Epub 2020 Aug 7. doi: 10.1053/j.gastro.2020.08.00. PMID: 32777286. PMCID: PMC9440641.

61. Sanford NN, Dharwadkar P, **Murphy CC***. (invited by Frank Berger, MD). Early-onset colorectal cancer: more than two sides to the story? *Colorectal Cancer* 2020; 9(3):CRC28. Epub 2020 Oct 19. doi: 10.2217/crc-2020-0016.
62. Abualkhair WH, Zhou M, Ochoa CO, Lacayo L, **Murphy C**, Wu XC, Karlitz JJ. Geographic and intra-racial disparities in early-onset colorectal cancer in the SEER 18 registries of the United States. *Cancer Med* 2020; 9(23):9150-9159. Epub 2020 Oct 22. doi: 10.1002/cam4.3488. PMID: 33094553. PMCID: PMC7724480.
63. Han S, Kolb, JM, Hosokawa P, Friedman C, Fox C, Scott FI, Lieu C, Vajravelu RK, McCarter M, **Murphy CC**, Cook MB, Gleisner A, Falk GW, Katzka DA, Wani S. The volume-outcome effect calls for centralization of care in esophageal adenocarcinoma: results from a large national cancer registry. *Am J Gastroenterol* 2020; 116(4):811-815. Epub 2020 Nov 23. doi: 10.14309/ajg.0000000000001046. PMID: 33229980.
64. Desai N, Riche NE, Jan MK, Perrman P, McBryde J, Blackwell JM, Quirk L, Clark C, **Murphy CC**, Villarreal D, Waljee A, Gopal P, Singal AG. Randomized clinical trial of inreach with or without mailed outreach to promote hepatitis C screening in a difficult-to-reach patient population. *Am J Gastroenterol* 2021; 116(5):976-983. Epub 2020 Dec 17. doi: 10.14309/ajg.0000000000001085. PMID: 33337657.
65. Dharwadkar P, Greenan G, Stoffel EM, Burstein E, Pirzadeh-Miller S, Lahiri S, Mauer C, Singal AG, **Murphy CC***. Racial and ethnic disparities in germline genetic testing of patients with young-onset colorectal cancer. *Clin Gastroenterol Hepatol* 2022; 20(2):353-361. Epub 2020 Dec 24. doi: 10.1016/j.cgh.2020.12.025. PMID: 33359728. PMCID: PMC8222407.
66. Demb J, Liu L, **Murphy CC**, Doubeni CA, Martinez ME, Gupta S. Young-onset colorectal cancer risk among individuals with iron deficiency anemia and hematochezia. *Gut* 2020. Epub 2020 Dec 18. doi: 10.1136/gutjnl-2020-321849. PMID: 33443020. PMCID: PMC8284839.
67. **Murphy CC**, Lupo PJ, Roth M, Winick N, Pruitt SL. Disparities in cancer survival among adolescents and young adults: a population-based study of 88,000 patients. *J Natl Cancer Inst* 2021; 113(8):1074-1083. Epub 2021 Jan 23. doi: 10.1093/jnci/djab006. PMID: 33484568. PMCID: PMC8328976.
68. Lee SJC, **Murphy CC**, Gerber DE, Geiger AM, Halm EA, Nair RG, Cox JV, Tiro JA, Skinner CS. Reimbursement matters: overcoming barriers to clinical trial accrual. *Med Care* 2021; 59(5):461-466. Epub 2021 Jan 22. doi: 10.1097/MLR.0000000000001509. PMID: 33492049. PMCID: PMC8026490.
69. Pruitt SL, Zhu H, Heitjan DF, Rahimi A, Maddineni B, Tavakkoli A, Halm EA, Gerber DE, Xiong D, **Murphy CC**. Survival of women diagnosed with breast cancer and who have survived a previous cancer. *Breast Cancer Res Treat* 2021; 187(3):853-865. Epub 2021 Feb 23. doi: 10.1007/s10549-021-06122-w. PMID: 33620590. PMCID: PMC8318112.
70. Vernon SW, del Junco DJ, Coan SP, **Murphy CC**, Walters ST, Friedman RH, Bastian LA, Fisher DA, Lairson DR, Myers RE. A stepped randomized trial to promote colorectal cancer screening in a nationwide sample of U.S. veterans. *Contemp Clin Trials* 2021; 105:106392. Epub 2021 Apr

3. doi: 10.1016/j.cct.2021.106392. PMID: 33823295. PMCID: PMC8172445.

71. Sapena V, Enea M, Torres F, Celsa C, Rios J, Emanuele G, Rizzo M, Nahon P, Marino Z, Tateishi R, Minami T, Sangiovanni A, Fornis X, Toyoda H, Brillanti S, Conti F, Degasperis E, Yu M, Tsai P, Jean K, El Kassas M, Shousha HI, Abdelaziz AO, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, **Murphy C**, Kohla M, Masetti C, Dufour J, Merchante N, Cavelletto L, Chemello L, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Camma C, Bruix J, Cabibbo G, Reig M. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. *Gut* 2022; 71(3):595-604. Epub 2021 Mar 19. doi: 10.1136/gutjnl-2020-323663. PMID: 33741640.
72. Pruitt SL, Gerber DE, Zhu H, Heitjan DF, Maddineni B, Xiong D, Singal AG, Tavakkoli A, Halm EA, **Murphy CC**. Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer. *Cancer Medicine* 2021; 10(14):4762-4767. Epub 2021 June 30. doi: 10.1002/cam4.4036. PMID: 34190429. PMCID: PMC8290226.
73. **Murphy CC**, Fullington HM, Gerber DE, Bowman IA, Puligandla M, Dutcher JP, DiPaola RS, Haas NB. Adherence to oral therapies among patients with renal cell carcinoma: post hoc analysis of the ECOG-ACRIN E2805 trial. *Cancer Med* 2021; 10(17):5917-5924. Epub 2021 Aug 18. doi: 10.1002/cam4.4140. PMID: 34405965. PMCID: PMC8419781.
74. **Murphy CC**, Cirillo PM, Krigbaum NY, Singal AG, Lee M, Zaki T, Burstein E, Cohn BA. Maternal obesity, pregnancy weight gain, and birth weight and risk of colorectal cancer. *Gut* 2022; 71(7):1332-1339. Epub 2021 Aug 24. doi: 10.1136/gutjnl-2021-325001. PMID: 34429385. PMCID: PMC8866526.

Selected media coverage: Maternal health may play a big role in who gets colorectal cancer. KPRC-TV Houston. September 10, 2021. <https://www.click2houston.com/news/local/2021/09/11/maternal-health-may-play-a-big-role-in-who-gets-colorectal-cancer/>

Cassandra Willyard. The colon cancer conundrum. *Scientific American*. December 1, 2021; S12. <https://www.scientificamerican.com/article/the-colon-cancer-conundrum/>
75. Lee JK, Merchant SA, Jensen CD, **Murphy CC**, Udaltsova N, Corley DA. Rising early-onset colorectal cancer is not an artifact of increased screening colonoscopy use in a large, diverse healthcare system. *Gastroenterology* 2022; 162(1):325-327. Epub 2021 Sept 20. doi: 10.1053/j.gastro.2021.09.034. PMID: 34555382. PMCID: PMC8678196.
76. Peery AF, Crockett SD, **Murphy CC**, Jensen ET, Kim HP, Egberg MD, Lund JL, Moon AW, Pate V, Barnes EL, Schlusser CL, Baron TH, Shaheen NJ, Sandler RS. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2021. *Gastroenterology* 2022; 162(2):621-644. Epub 2021 Oct 19. doi: 10.1053/j.gastro.2021.10.017. PMID: 34678215.
77. Cohn BA‡, Cirillo PM‡, **Murphy CC‡**, Krigbaum NY, Wallace AW. SARS-CoV-2 vaccine protection and deaths among U.S. Veterans during 2021. *Science* 2022; 375(6578):331-336. Epub 2021 Nov 4. doi: 10.1126/science.abm062. PMID: 34735261. ‡contributed equally

Selected media coverage: Melissa Healy. Study shows dramatic decline in effectiveness of all three COVID-19 vaccines over time. *Los Angeles Times*. November 4, 2021. <https://www.latimes.com/science/story/2021-11-04/study-shows-dramatic-decline-in-effectiveness-of-covid-19-vaccines>

Laura McGinley, Lena H. Sun, and Tyler Page. Pfizer-BioNTech expected to seek authorization for coronavirus booster for people 18 and older. *Washington Post*. November 9, 2021. <https://www.washingtonpost.com/health/2021/11/08/pfizer-biontech-coronavirus-booster-authorization-18-and-older/>

78. Zaki T, Singal AG, May FP, **Murphy CC***. Increasing incidence rates of colorectal cancer at age 50-54 years. *Gastroenterology* 2022; 162(3):964-965. Epub 2021 Oct 29. doi: 10.1053/j.gastro.2021.10.039. PMID: 34757141. PMCID: PMC8881296.
79. **Murphy CC**, Cirillo PM, Krigbaum NY, Cohn BA. In utero exposure to 17 α -hydroxyprogesterone caproate and risk of cancer in offspring. *Am J Obstet Gynecol* 2022; 226(1):132.e1-132.e14. Epub 2021 Nov 9. doi: 10.1016/j.ajog.2021.10.035. PMID: 34767803. PMCID: PMC8748293.
- Selected media coverage:* Melody Petersen. A drug for pregnant women doesn't work, according to the FDA. A company is selling it anyway. *Los Angeles Times*. February 17, 2022. <https://www.latimes.com/business/story/2022-02-17/makena-covis-premature-birth-pregnant-womens-health>
- Editorial Board. FDA should pull ineffective pregnancy drug Makena until we know it works. *Los Angeles Times*. February 24, 2022. <https://www.latimes.com/opinion/story/2022-02-24/editorial-does-this-drug-work-stop-selling-it-until-we-know>
- Ariana Eunjung Cha. FDA wants to yank pregnancy drug. Firm argues Black women will suffer. *Washington Post*. October 17, 2022. <https://www.washingtonpost.com/health/2022/10/17/preterm-birth-makena-fda-black-women/>
80. **Murphy CC**, Halm EA, Zaki T, Johnson C, Yekkaluri S, Quirk L, Singal AG. Colorectal cancer screening and yield in a mailed outreach program in a safety-net healthcare system. *Dig Dis Sci* 2022; 67(9):4403-4409. Epub 2021 Nov 20. doi: 10.1007/s10620-021-07313-7. PMID: 34800219. PMCID: PMC8605769.
81. Fudman DI, Singal AG, Cooper MG, Lee M, **Murphy CC***. Prevalence of forceps polypectomy of non-diminutive polyps is substantial but modifiable. *Clin Gastroenterol Hepatol* 2022; 20(7):1508-1515. Epub 2021 Nov 25. doi: 10.1016/j.cgh.2021.11.031. PMID: 34839039. PMCID: PMC9133266.
82. Singal AG, Reddy S, Patel HR, Villarreal D, Khan A, Liu Y, Rich NE, **Murphy CC**, Tiro JA, Kramer JR, Hernaez R. Multi-center randomized clinical trial of a mailed outreach strategy for hepatocellular carcinoma surveillance. *Clin Gastroenterol Hepatol* 2021. Epub 2021 Dec 10. doi: 10.1016/j.cgh.2021.12.014. PMID: 34902568. PMCID: PMC9184300.
83. Schoenberger H, Rich NE, Jones P, Yekkaluri S, Yopp A, Singal AG, **Multi-Ethnic HCC**

- Cohort Investigators.** Racial and ethnic disparities in barriers to care in patients with hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2021. Epub 2021 Dec 26. doi: 10.1016/j.cgh.2021.12.027. PMID: 34965448. PMCID: PMC9233716.
84. Betts AC, **Murphy CC***, Shay LA, Balasubramanian BA, Markham C, Allicock A. Polypharmacy and prescription medication use in a population-based sample of adolescent and young adult cancer survivors. *J Cancer Surviv* 2022. Epub 2022 Jan 8. doi: 10.1007/s11764-021-01161-0. PMID: 34997910.
 85. Kapinos KA, Halm EA, **Murphy CC**, Santini NO, Loewen AC, Skinner CS, Singal AG. Cost effectiveness of mailed outreach programs for colorectal cancer screening: analysis of a pragmatic, randomized trial. *Clin Gastroenterol Hepatol* 2022; 20(10):2383-2392. Epub 2022 Feb 3. doi: 10.1016/j.cgh.2022.01.054. PMID: 35144024. PMCID: PMC9357235.
 86. Jan J, Osho A, **Murphy CC**, Mazure CM, Singal AG, Rich NE. Gender, age, racial and ethnic disparities in clinical trial enrollment for primary liver cancer. *Gastroenterology* 2022; 163(1):14-20.e2. Epub 2022 Mar 11. doi: 10.1053/j.gastro.2022.03.015. PMID: 35288115. PMCID: PMC9232956.
 87. Dharwadkar P, Zaki T, **Murphy CC*** (invited by Kimmie Ng, MD and Benjamin Schlechter, MD). Colorectal cancer in young adults. *Hematol Oncol Clin N Am* 2022; 36(3):449-470. Epub 2022 May 13. doi: 10.1016/j.hoc.2022.02.005. PMID: 35577711. PMCID: PMC9177054.
 88. Coronado GD, Dickerson JF, Burnett-Hartman AN, Carethers JM, Lee J, McBurnie MA, **Consortium for Early Onset Colorectal Cancer**. Reduced implementation and completion of average-risk annual FIT colorectal cancer screening in Black patients aged 45-49 years. *Clin Gastroenterol Hepatol* 2022. Epub 2022 May 26. doi: 10.1016/j.cgh.2022.05.009. PMID: 35644342.
 89. Pruitt SL, Tavakkoli A, Zhu H, Heitjan DF, Gerber DE, Singal AG, Halm EA, Beg S, Maddineni B, **Murphy CC**. Survival of cancer survivors with a new pancreatic cancer diagnosis. *Cancer Med* 2022. Epub 2022 June 8. doi: 10.1002/cam4.4903. PMID: 35674139.
 90. Liu PH, Singal AG, **Murphy CC***. No increase in colorectal cancer screening in 2019 after American Cancer Society recommends starting screening at age 45. *Clin Gastroenterol Hepatol* 2022. Epub 2022 June 11. doi: 10.1016/j.cgh.2022.05.030. PMID: 35700888.
 91. Zaki TA, Liang PS, May FP, **Murphy CC***. Racial and ethnic disparities in early-onset colorectal cancer survival. *Clin Gastroenterol Hepatol* 2022. Epub 2022 June 16. doi: 10.1016/j.cgh.2022.05.035. PMID: 35716905.
 92. Tavakkoli A, Pruitt SL, Hoang AQ, Zhu H, Hughes AE, McKey TA, Elmunzer BJ, Kwon RS, **Murphy CC*†**, Singal AG‡. Ethnic disparities in early-onset gastric cancer: a population-based study in Texas and California. *Cancer Epidemiol Biomarkers Prev* 2022; 31(9):1710-1719. Epub 2022 June 22. doi: 10.1158/1055-9965.EPI-22-0210. PMID: 35732290. PMCID: PMC9444918. †co-senior authors
 93. Liu PH, Sanford NN, Liang PS, Singal AG, **Murphy CC***. Persistent disparities in colorectal cancer screening: a tell-tale sign for implementing new guidelines in younger adults. *Cancer*

Epidemiol Biomarkers Prev 2022; 31(9):1701-1709. Epub 2022 June 23. doi: 10.1158/1055-9965.EPI-21-1330. PMID: 35765830. PMCID: PMC9444917.

Invited commentary by: Brawley OW. On the potential for optimizing colorectal screening outcomes. Cancer Epidemiol Biomarkers Prev 2022; 31(9):1671-1672. doi: 10.1158/1055-9965.EPI-22-0618. PMID: 36052488.

94. Perez M, **Murphy CC**, Pruitt SL, Rashdan S, Rahimi A, Gerber DE. Potential impact of revised NCI eligibility criteria guidance: prior malignancy exclusion in breast cancer clinical trials. J Natl Compr Canc Netw 2022; 20(7):792-799.e4. doi: 10.6004/jnccn.2022.7017. PMID: 35830895.
95. **Murphy CC**, Betts AC, Allicock MA, Shay LA, Preston SM, Cohn BA, Lupo PJ, Pruitt SL. Stillbirth after adolescent and young adult cancer: a population-based study. J Natl Cancer Inst 2022. Epub 2022 Aug 27. doi: 10.1093/jnci/djac168. PMID: 36029247.
96. Banegas MP, Dickerson JF, Zheng Z, **Murphy CC**, Tucker-Seeley R, Murphy JD, Yabroff KR. Association of social risk factors with mortality among US adults with a new cancer diagnosis. JAMA Netw Open 2022; 5(9):e2233009. Epub 2022 Sep 1. doi: 10.1001/jamanetworkopen.2022.33009. PMID: 36112380. PMCID: PMC9482059.
97. Betts AC, Shay LA, Allicock M, Preston SM, Grimes A, **Murphy CC***. Impacts of the COVID-19 pandemic among a nationally representative sample of adolescent and young adults with a history of cancer in the U.S. J Adolesc Young Adult Oncol 2022. Epub 2022 Sep 29. doi: 10.1089/jayao.2022.0045. PMID: 36173754.
98. Betts AC, **Murphy CC***, Shay LA, Balasubramanian BA, Markham C, Roth ME, Allicock M. Polypharmacy and medication nonadherence in a population-based sample of adolescent and young adults with a history of cancer, 2008-2017. J Cancer Surviv 2022. Epub 2022 Nov 8. doi: 10.1007/s11764-022-01274-0. PMID: 36346577.
99. Xie L, Gelfand A, **Murphy CC***, Mathew MS, Atem F, Delclos GL, Messiah S. Prevalence of polypharmacy and associated adverse outcomes and risk factors among children with asthma in the USA: a cross-sectional study. BMJ Open 2022; 12(10):e064708. Epub 2022 Oct 13. doi: 10.1136/bmjopen-2022-064708. PMID: 36229143.
100. Singal AG, Masica A, Esselink K, **Murphy CC**, Dever JA, Reczek A, Bensen M, Mack N, Stutts E, Ridenhour JL, Galt E, Brainerd J, Kopplin N, Yekkaluri S, Rubio C, Anderson S, Jan K, Whitworth N, Wagner J, Allen S, Muthukumar AR, Tiro J. Population-based correlates of COVID-19 infection: an analysis from the DFW COVID-19 Prevalence Study. PLoS One 2022; 17(12):e0278335. Epub 2022 Dec 1. doi: 10.1371/journal.pone.0278335. PMID: 36454745.
101. Cavestro Giulia M, Mannucci A, Balaguer F, Hampel H, Kupfer SS, Repici A, Sartore-Bianchi A, Seppälä Toni T, Valentini V, Boland Clement R, Brand RE, Buffart TE, Burke CA, Caccialanza R, Cannizzaro R, Cascinu S, Cercek A, Crosbie EJ, Danese S, Dekker E, DacaAlvarez M, Deni F, Dominguez-Valentin M, Eng C, Goel A, Guillem Josè G, Houwen B, Kahi C, Kalady MF, Kastrinos F, Kühn F, Laghi L, Latchford A, Liska D, Lynch P, Malesci A, Mauri G, Meldolesi E, Møller P, Monahan KJ, Moslein G, **Murphy CC**, Nass K, Ng K, Oliani

- C, Papaleo E, Patel SG, Puzzono M, Remo A, Ricciardiello L, Ripamonti Carla I, Siena S, Singh SK, Stadler ZK, Stanich PP, Syngal S, Turi S, Urso Emanuele D, Valle L, Vanni Valeria S, Vilar E, Vitellaro M, You Y-QN, Yurgelun MB, Zuppardo Raffaella A, Stoffel EM, on behalf of the Associazione Italiana Familiarità Ereditarietà Tumori, Collaborative Group of the Americas on Inherited Gastrointestinal Cancers, European Hereditary Tumor Group, and International Society for Gastrointestinal Hereditary Tumours. Delphi initiative for early-onset colorectal cancer (DIRECt) International Management Guidelines. *Clin Gastroenterol Hepatol* 2022. Epub 2022 Dec 19. doi: 10.1016/j.cgh.2022.12.006. PMID: 36549470.
102. Liu PH, Singal AG, **Murphy CC***. Stool-based tests mitigate impacts of COVID-19 on colorectal cancer screening. *Clin Gastroenterol Hepatol* 2022. Epub 2022 Dec 22. doi: 10.1016/j.cgh.2022.12.014. PMID: 36566814. PMCID: PMC9780015.
 103. Meernik C, Jorgensen K, Wu CF, **Murphy CC**, Baker VL, Brady PC, Nitecki R, Nichols HB, Rauh-Hain JA. Disparities in the use of assisted reproductive technologies after breast cancer: a population-based study. *Breast Cancer Res Treat* 2023. Epub 2023 Jan 6. doi: 10.1007/s10549-022-06857-0. PMID: 36607486.
 104. Jorgensen K, Meernik C, Wu CF, **Murphy CC**, Baker VL, Jarmon P, Brady PC, Nitecki R, Nichols HB, Rauh-Hain JA. Disparities in fertility-sparing treatment and use of assisted reproductive technology after diagnosis of cervical, ovarian, or endometrial cancer. *Obstet Gynecol* 2023;141(2):341-53. Epub 2023 Jan 4. doi: 10.1097/aog.0000000000005044. PMID: 36649345. PMCID: PMC9858239.
 105. **Murphy CC**, Cirillo PM, Krigbaum NY, Singal AG, Zaki T, Jones DP, Cohn BA. In-utero exposure to antibiotics and risk of colorectal cancer in a prospective cohort of 18,000 adult offspring. *Int J Epidemiol* 2023. Epub 2023 Jan 24. doi: 10.1093/ije/dyad004. PMID: 36692207.

Commentaries, Book Chapters, and Other Publications

1. **Murphy CC**, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Reply to: A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. *Breast Cancer Res Treat* 2013; 138(1):328. Epub 2013 Feb 12. doi: 10.1007/s10549-013-2422-4. PMID: 23400580.
2. Vernon SW, **Murphy CC**, McQueen A. Colorectal Cancer Screening. In Holland JC, Breitbart WS, Jacobsen PB, Lederberg MG, Loscalzo MJ, McCorkle R (eds). *Psycho-Oncology*, 3rd edition. New York: Oxford University Press. 2015. ISBN: 9780199363315.
3. **Murphy CC**, Baron JA (invited editorial). Colorectal cancer in older ages: what's ahead? *Clin Gastroenterol Hepatol* 2017; 15(6):901-2. Epub 2017 Jan 28. doi: 10.1016/j.cgh.2017.01.019. PMID: 28143729.
4. Atiq O, Tiro J, Yopp AC, Muffler A, Marrero JA, Parikh ND, **Murphy C**, McCallister K, Singal AG. HCC surveillance: striving for a better balance of benefits and harms. *Hepatology* 2017; 66(3):1002-3. Epub 2017 May 24. doi: 10.1002/hep.29286. PMID: 28543272.
5. **Murphy CC**, Sanoff HK, Stitzenberg KB, Baron JA, Sandler RS, Yang YC, Lund JL. Reply to:

- Colorectal cancer incidence patterns in the United States, 1974–2013. *J Natl Cancer Inst* 2017; 109(8):dix104. Epub 2017 Aug 2. doi: 10.1093/jnci/dix104. PMID: 29117391. PMCID: PMC6440264.
6. **Murphy CC**, Yang YC (invited review by Allison Aiello, PhD). Use of age-period-cohort analysis in cancer epidemiology research. *Curr Epidemiol Rep* 2018; 5(4):418-31. Epub 2018 Oct 3. doi: 10.1007/s40471-018-0174-8. PMID: 31011507. PMCID: PMC6474378.
 7. Singal AG, **Murphy CC** (invited editorial). Hepatocellular carcinoma: a roadmap to reduce incidence and future burden. *J Natl Cancer Inst* 2018; 111(6):527-8. Epub 2018 Dec 13. doi: 10.1093/jnci/djy18. PMID: 30544135. PMCID: PMC6579741.
 8. Singal AG, **Murphy CC**. Hepatocellular carcinoma surveillance: an effective but complex process. *Gastroenterology* 2019; 156(4):1215. Epub 2018 Dec 10. doi: 10.1053/j.gastro.2018.08.066. PMID: 30543799.
 9. Dwyer AJ, **Murphy CC**, Boland CR, Garcia R, Hampel H, Limburg P, Lowery J, Zauber AG, Waring S, Worrall S, Perea J, Sigel R, Lee J, Molmenti C, Sears CL, Buckhaults P, Hayes R, Hussan H, de Miranda N, Palles C, Diaz L, Song M, Cercek A, Lieu CH, Patel SG, Karlitz JJ, Cao Y, Demb J, Blatchford P, Risendal B, Weltzien E, Wali A, Dascher P, Loomans-Kropp H, Levell CL, Wehling K, Martin J, Pesmen C, Kuchar V, Soisson R, Davis A, Ahnen D. A summary of the Fight Colorectal Cancer working meeting: exploring risk factors and etiology of sporadic early-age onset colorectal cancer. *Gastroenterology* 2019; 157(2):280-8. Epub 2019 May 13. doi: 10.1053/j.gastro.2019.04.049. PMID: 31095950.
 10. Singal AG, Parikh ND, **Murphy CC**. Reply to: Did direct-acting antiviral therapy for hepatitis C virus infection really improve the survival of patients with hepatocellular carcinoma? *Gastroenterology* 2020; 158(6):1844. Epub 2020 Feb 18. doi: 10.1053/j.gastro.2020.02.024. PMID: 32084426.
 11. **Murphy CC**, Vernon SW. Colorectal Cancer Screening. In Breitbart WS, Butow PN, Jacobsen PB, Lam WWT, Lazenby M, Loscalzo MJ (eds). *Psycho-Oncology*, 4th edition. New York: Oxford University Press. 2021. ISBN: 9780190097653.
 12. Lee JK, Burnett-Hartman A, **Murphy CC** (invited editorial). Sugary truth of early-onset colorectal neoplasia – not so sweet after all. *Gastroenterology* 2021; 161(1):27-29. Epub 2021 Apr 24. doi: 10.1053/j.gastro.2021.04.046. PMID: 33905675.
 13. Patel S, **Murphy CC**, Liu C, Hampel H. Early Age Onset Colorectal Cancer. In Berger F, Boland CR (eds). *Novel Approaches to Colorectal Cancer*, Volume 151 in the *Advances in Cancer Research* series. Cambridge, Massachusetts: Academic Press. 2021. ISBN: 9780128240786.
 14. **Murphy CC**, Cohn BA. Early life: an important window of susceptibility for colorectal cancer. *Gastroenterology* 2022; 163(2):532-533. Epub 2022 Jan 5. doi: 10.1053/j.gastro.2022.01.003. PMID: 35007514. PMCID: PMC9259754.
 15. **Murphy CC**‡, Paskett ED‡, Pruitt SL‡ (invited editorial). The influence of place and geography on outcomes across the cancer continuum. *Gastroenterology* 2022; 163(2):369-371. Epub 2022

Jun 4. doi: 10.1053/j.gastro.2022.06.009. PMID: 35671802. ‡contributed equally

16. Lieberman D, Ladabaum U, Brill JV, May FP, Kim L, **Murphy C**, Wender R, Teixeira K. Reducing the burden of colorectal cancer: AGA positions statements. *Gastroenterology* 2022; 163(2):520-526. Epub 2022 June 14. doi: 10.1053/j.gastro.2022.05.011. PMID: 35715380.
17. Burnett-Hartman AN, **Murphy CC**, Lee JK (invited editorial). Novel, emerging risk factors for colorectal cancer remain understudied. *Gastroenterology* 2022; 163(3):574-576. Epub 2022 Jul 7. doi: 10.1053/j.gastro.2022.06.085. PMID: 35809616.

Manuscripts under Review

1. **Murphy CC**, Lee JK, Liang PS, May FP, Zaki TA. Declines in colorectal cancer incidence and mortality rates slow among older adults. *Am J Gastroenterol* (submitted 11/2022).
2. **Murphy CC**, Tortolero GA, Gerber DE, Pruitt SL. Prevalence of prior cancer among persons newly diagnosed with cancer: an updated report from the Surveillance, Epidemiology, and End Results program. *JAMA Oncol* (submitted 11/2022).
3. **Murphy CC**, Cirillo PM, Krigbaum NY, Singal AG, Cohn BA. In utero exposure to anti-emetic increases risk of adult-onset colorectal cancer. *J Natl Cancer Inst* (submitted 12/2022).
4. Betts AC, Shay LA, Lupo PJ, Pruitt SL, Roth ME, Allicock MA, Cohn BA, **Murphy CC***. Adverse birth outcomes of adolescent and young adult women diagnosed with cancer during pregnancy: a population-based study. *J Natl Cancer Inst* (submitted 12/2022).

Research Support

Current

RWIA-136937	Murphy (PI)	10/1/2022—9/30/2023
American Cancer Society/Flatiron Health		
<i>Racial and Ethnic Disparities in Treatment Patterns Among Young Adults with Cancer</i>		
Goal: Characterize treatment patterns among young adults diagnosed with metastatic breast and colorectal cancer and examine differences in receipt of first-line therapy by race and ethnicity.		
Role: Principal Investigator		
RSG-21-046	Murphy (PI)	7/1/2021—6/30/2025
American Cancer Society		
<i>Co-payments and Adherence to Oral Endocrine Therapy in a Safety-net System</i>		
Goal: Characterize initiation, persistence, and compliance with endocrine therapy among low-income and uninsured women and determine impact of co-payment on persistence and compliance.		
Role: Principal Investigator		
R01 CA242558	Murphy (PI)	9/1/2019—8/31/2024
National Cancer Institute		
<i>Early Life Exposures and Risk of Young-Onset Colorectal Cancer</i>		
Goal: Examine the association between environmental exposures in early life (antibiotics, cesarean		

delivery, birth weight, and childhood obesity) and young-onset colorectal cancer; and explore whether early life exposures modify the association between family history and young-onset disease.
Role: Principal Investigator

CA181215 Murphy (PI) 6/1/2019—10/31/2023

U.S. Department of Defense

Fertility and Reproductive Outcomes of Adolescent and Young Adult Cancer Survivors in Texas

Goal: Characterize fertility and reproductive outcomes among adolescent and young adult cancer survivors and estimate risk of birth defects in this population.

Role: Principal Investigator

R01 CA229834 Pruitt (PI) 7/1/2018—6/30/2023

National Cancer Institute

Revisiting Prior Cancer as an Exclusion Criterion for Cancer Clinical Trials

Goal: Assess frequency and type of exclusion criteria related to prior cancer in NCI-sponsored trials; quantify the impact of prior cancer on survival among patients newly diagnosed with breast, colorectal, kidney, liver, and pancreatic cancers and non-Hodgkin lymphoma.

Role: Co-Investigator

Completed

UM1 CA221940 Tiro/Skinner/Haas/Kamineni (MPI) 4/1/2018—5/31/2021

National Cancer Institute

Multi-level Optimization of the Cervical Cancer Screening Process in Diverse Settings & Populations

Goal: Examine multi-level factors facilitating delivery of cervical cancer screening and treatment in three diverse U.S. healthcare systems.

Role: Co-Investigator

UM1 CA222035 Corley/Chubak/Halm/Kamineni/Schottinger/Skinner (MPI) 4/1/2018—5/31/2021

Optimizing Colorectal Cancer Screening Precision and Outcomes in Community-based Populations

Goal: To characterize potential failures of the colorectal cancer screening process, improve accuracy of screening tests, and develop screening strategies tailored to personal risk.

Role: Co-Investigator

R01 MD012565 Singal/Yopp (MPI) 3/1/2018—5/31/2021

National Institute on Minority Health and Health Disparities

Multi-level Factors for Racial/Ethnic and Socioeconomic Disparities in Prognosis of Hepatocellular Carcinoma

Goal: Characterize racial/ethnic and socioeconomic disparities in tumor stage, receipt of timely treatment, and overall survival in a cohort of patients newly diagnosed with hepatocellular carcinoma across four diverse U.S. healthcare systems.

Role: Co-Investigator

PP160075 Singal (PI) 9/1/2016—5/31/2021

Cancer Prevention and Research Institute of Texas

Implementing an Evidence-based Colorectal Cancer Screening Outreach Program

Goal: Conduct a colorectal cancer screening outreach program among 18,000 screen-eligible patients

receiving care in a safety-net healthcare system.

Role: Co-Investigator

KL2 TR001103 Toto (PI) 7/1/2017—4/30/2019

National Center for Advancing Translational Sciences

Clinical and Translational Research Scholars Program

Goal: Provide research training and career development opportunities in a multidisciplinary setting and prepare junior investigators for a successful career in clinical and translational research.

Role: Scholar

Translational Research Pilot Program Abrams (PI) 3/1/2017—2/28/2019

Harold C. Simmons Comprehensive Cancer Center

Dysregulated Mobile Elements as Drivers of Colorectal Cancer

Goal: Characterize retrotransposon dysregulation across the adenoma-carcinoma transition and examine association between nucleoside reverse transcriptase inhibitors and colorectal neoplasia.

Role: Co-Investigator

Small Pilot Awards Program Murphy (PI) 5/1/2017—9/30/2018

Center for Patient-Centered Outcomes Research

University of Texas Southwestern Medical Center

Patient Experiences with and Adherence to Oral Anticancer Therapies

Goal: Through semi-structured interviews with cancer patients and caregivers, identify patient-level factors contributing to management and adherence to oral anticancer therapy.

Role: Principal Investigator

AcademyHealth Murphy (PI) 1/1/2017—12/31/2017

Patterns of Prescription Medication Use and Polypharmacy among Cancer Survivors

Goal: Characterize patterns of prescription medication use, polypharmacy, and prescription expenditures among cancer survivors receiving care across diverse settings and populations.

Role: Principal Investigator

U54 CA163308-05S1 Skinner/Halm (MPI) 9/1/2016—11/30/2017

National Cancer Institute

National Survey on Oncologist Reimbursement & EHR-based Tools

Goal: Administer a nationally representative survey of oncologists on barriers and facilitators to clinical trial accrual.

Role: Co-Investigator

T32 DK007634 Sandler (PI) 7/1/2013—6/30/2016

National Institute of Diabetes and Digestive and Kidney Diseases

Digestive Disease Epidemiology Training Program

Goal: Train pre- and post-doctoral candidates to improve the understanding of the magnitude, etiology and impact of digestive diseases, and to assume leadership roles in GI epidemiology and outcomes research.

Role: Predoctoral Fellow

PhRMA Foundation Lund (PI) 1/1/2015—12/31/2015

Heterogeneity of Treatment Effectiveness and Safety among Older Patients with Colon Cancer

Goal: Describe determinants of adjuvant chemotherapy initiation and completion, evaluate the comparative effectiveness and safety of adjuvant oxaliplatin vs. 5-FU, and examine potential heterogeneity of treatment effects across comorbidity and functional status subgroups in a cohort of older patients with colon cancer.

Role: Graduate Research Assistant

Laura W. Bush Institute for Women's Health Alvarez (PI) 12/1/2013—11/30/2014

Initiation of Adjuvant Hormonal Therapy among Underserved Breast Cancer Survivors

Goal: Examine initiation of adjuvant hormonal therapy (e.g., tamoxifen and aromatase inhibitors) over a 4-year period among breast cancer survivors receiving care through Dallas' Parkland Health & Hospital System, one of the largest integrated safety-net healthcare systems in the U.S.

Role: Consultant

R01 CA112223 Vernon (PI) 9/1/2011—7/31/2013

National Cancer Institute

Initiation of Colon Cancer Screening in Veterans

Goal: Conduct a randomized controlled trial to develop and test stepped interventions to increase initial uptake of colorectal cancer screening in a nationally representative, ethnically diverse sample of male and female veterans.

Role: Project Director

Teaching Experience

Coursework

EPID 600: Principles of Epidemiology for Public Health (Graduate Teaching Assistant)

Department of Epidemiology, University of North Carolina at Chapel Hill

Spring 2016

PHDA 5098: Public Health and Medicine (Guest Lecturer)

University of Texas School of Public Health, Dallas Regional Campus

Spring 2017

CTM 5301: Clinical Research Design & Analysis (Guest Lecturer)

University of Texas Southwestern Medical Center

Fall 2017, Fall 2018, Fall 2020

CTM 5207: Introduction to Patient-Centered Outcomes Research (Guest Lecturer)

University of Texas Southwestern Medical Center

Spring 2018

PHD 1435: Health Promotion and Behavioral Sciences Research Seminar (Co-Instructor)

UTHealth School of Public Health

Summer 2021, Fall 2022, Spring 2023

PHWM/PHWD 1120: Program Evaluation (Lead Instructor)

UTHealth School of Public Health

Summer 2022

Presentations at Scientific Meetings

** indicates role as faculty mentor*

† indicates role as lead methodologist

1. Carpentier MY, Vernon SW, Bartholomew LK, **Murphy CC**, Bluethmann SM. Receipt of recommend surveillance guidelines among colorectal cancer survivors: a systematic review. Poster presentation at the 6th Biennial Cancer Survivorship Research Conference: Translating Science into Care, Arlington, VA, June 2012.
2. Bluethmann SM, Bartholomew LK, Vernon SW, **Murphy CC**, Carpentier MY. Bridging the transition: a systematic review and meta-analysis of physical activity interventions and behavior change in post-treatment breast cancer survivors. Poster presentation at the 6th Biennial Cancer Survivorship Research Conference: Translating Science into Care, Arlington, VA, June 2012.
3. Savas LS, Bartholomew LK, Carpentier MY, **Murphy CC**, Haddock NM, Vernon SW. Correlates of breast cancer survivor surveillance behavior: a hospital-based registry pilot study. Poster presentation at the 6th Biennial Cancer Survivorship Research Conference: Translating Science into Care, Arlington, VA, June 2012.
4. Opusunju JJ, **Murphy CC**, Vernon SW, Bartholomew LK. Characteristics of patient navigation and the use of behavioral theory in interventions to promote colorectal cancer screening: a systematic review. Poster presentation at the 3rd Annual Cancer Prevention and Research Institute of Texas (CPRIT) Conference, Austin, TX, October 2012.
5. **Murphy CC**, Correa AM, Hofstetter WL. Trimodality therapy completion and treatment patterns of locally advanced esophageal adenocarcinoma patients in an off-protocol setting. Poster presentation at the 3rd Annual Cancer Prevention and Research Institute of Texas (CPRIT) Conference, Austin, TX, October 2012.
6. **Murphy CC**, Vernon SW, Diamond PM, Tiro JA. Competitive testing of health behavior theories: how do pros, cons, subjective norms, and intention influence mammography behavior? Paper presentation at the 34th Annual Meeting of the Society of Behavioral Medicine (SBM), San Francisco, CA, March 2013.
7. Bluethmann SM, Bartholomew LK, **Murphy CC**, Vernon SW. Analysis of behavior theory use in physical activity intervention development for breast cancer survivors. Poster presentation at the Energy Balance and Cancer Research Retreat, University of Texas M.D. Anderson Cancer Center, Houston, TX, February 2014.
8. **Murphy CC**, Vernon SW, Haddock NM, Anderson ML, Chubak J, Green BB. Longitudinal predictors of initial and repeat colorectal cancer screening. Oral presentation at the 20th Annual HMO Research Network Conference, Phoenix, AZ, April 2014.
9. Bluethmann SM, Bartholomew LK, **Murphy CC**, Vernon SW. Analysis of behavior theory use in physical activity intervention development for breast cancer survivors. Poster presentation

at the 35th Annual Meeting of the Society of Behavioral Medicine (SBM), Philadelphia, PA, April 2014.

10. **Murphy CC**, Harlan LC, Warren JL, Geiger AM. Racial disparities in the receipt of adjuvant chemotherapy among stage III colon cancer patients. Poster presentation at the American Association of Cancer Research (AACR) Science of Cancer Health Disparities Conference, San Antonio, TX, November 2014.
11. **Murphy CC**, Harlan LC, Lund JL, Lynch CF, Geiger AM. Patterns of colorectal cancer care in the United States: 1990-2010. Poster presentation at the 2015 Gastrointestinal Cancers Symposium, San Francisco, CA, January 2015.
12. Bluethmann SM, **Murphy CC**, Bartholomew LK, Tiro JA, Vernon SW. Adjuvant hormonal therapy and adherence decision in breast cancer survivors: a mixed-methods study. Poster presentation at the 36th Annual Meeting of the Society of Behavioral Medicine (SBM), San Antonio, TX, April 2015.
13. Fisher DA, Grubber J, **Murphy CC**, Johnson M, Sandler RS. Overuse and underuse of colonoscopy for screening and surveillance in an integrated managed care system. Poster presentation at the 2015 Digestive Disease Week (DDW), Washington, DC, May 2015.
14. Wheeler SB, **Murphy CC**, Reeder-Hayes K, Earp JA, Carey L, Olshan A. Endocrine therapy adherence, side effects, and risk perception among racially diverse breast cancer patients. Poster presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 2015.
15. **Murphy CC**, Tiro JA, Jean G, Balasubramanian BA, Higashi RT, Le B, Teng H, Alvarez CA. Initiation of adjuvant hormonal therapy among uninsured stage I-III breast cancer patients treated in a safety-net healthcare system. Poster presentation at the American Association of Cancer Research (AACR) Science of Cancer Health Disparities Conference, Atlanta, GA, November 2015.
16. Jean GW, **Murphy CC**, Tiro JA, Balasubramanian B, Teng H, Le B, Higashi RT, Alvarez CA. Initiation of adjuvant hormonal therapy among stage I-III breast cancer patients treated in a safety-net healthcare system. Poster presentation at the 12th Annual Meeting of the Hematology/Oncology Pharmacy Association (HOPA), Atlanta, GA, March 2016.
17. Lund JL, **Murphy CC**, Hinton SP, Sanoff HK, Stürmer T. Evaluating heterogeneity of adjuvant chemotherapy effectiveness among older adults diagnosed with stage III colon cancer. Poster presentation at the 2016 Epidemiology Congress of the Americas, Miami, FL, June 2016.
18. **Murphy CC**, Singal AG, Sanders JM, Pruitt SL, Lee SJC, Halm EA, Skinner CS. Patterns of repeat colorectal cancer screening and follow-up of abnormal results in an integrated safety-net healthcare system. Poster presentation at the 2017 Health Care Systems Research Network (HCSRN) Conference, San Diego, CA, March 2017.
19. Rich N, Yopp A, Odewole M, **Murphy C**,* Marrero J, Singal AG. Racial/ethnic disparities in hepatocellular carcinoma presentation and prognosis. Poster presentation at the 2nd Annual Internal Medicine Seldin Research Symposium, Dallas, TX, May 2017.

20. Sigel B, Yang E, Singal AG, McCallister K, Sanders JM, Skinner CS, Halm EA, **Murphy CC.*** Using 'proportion of days covered' to measure longitudinal adherence to colorectal cancer screening. Poster presentation at the 50th Annual Meeting of the Society for Epidemiologic Research (SER), Seattle, WA, June 2017.
21. **Murphy CC**, Fullington HM, Alvarez CA, Lee SJC, Betts A, Haggstrom DA, Halm EA. Polypharmacy and patterns of prescription medication use among cancer survivors. Poster presentation at the 42nd Annual Meeting of the American Society of Preventive Oncology (ASPO), New York, NY, March 2018.
22. **Murphy CC**, Fullington HM, Alvarez CA, Lee SJC, Betts A, Haggstrom DA, Halm EA. Polypharmacy and patterns of prescription medication use among cancer survivors. Poster presentation at Translational Science 2018, Washington, DC, April 2018.
23. **Murphy CC**, Skinner CS, Halm EA, Sanders JM, Singal AG. Patterns and yield of repeat fecal immunochemical test over four rounds of screening in a safety-net healthcare system. Podium presentation at the 2018 Digestive Disease Week (DDW), Washington, DC, June 2018.
24. Sen A, Sigel B, Singal AG, Mayo H, **Murphy CC***. A systematic review of failures across the colorectal screening process. Poster presentation at the 2018 Digestive Disease Week (DDW), Washington, DC, June 2018.
25. **Murphy CC**, Skinner CS, Gupta S, Halm EA, Ahn C, Sanders JM, McCallister K, Singal AG. A pragmatic, randomized trial of FIT vs. colonoscopy outreach: patterns of screening initiation by intervention dose. Podium presentation at the 2018 Digestive Disease Week (DDW), Washington, DC, June 2018.
26. **Murphy CC**, Fullington HM, Alvarez CA, Lee SJC, Betts A, Haggstrom DA, Halm EA. Polypharmacy and patterns of prescription medication use among cancer survivors. Podium presentation at the 2018 AcademyHealth Annual Research Meeting (focused session on opioid use), Seattle, WA, June 2018.
27. Dharwadkar P, Greenan G, Singal AG, **Murphy CC***. Young versus older-onset colorectal cancer in a safety-net hospital. Poster presentation at the American College of Gastroenterology (ACG) Annual Scientific Meeting, Philadelphia, PA, October 2018.
28. Singal AG, Rich NE, **Murphy CC[†]**, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld J, John B, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Modi A, Flores A, Satapathy S, Wong R, Huang A, Misra S, Schwartz M, Haste P, Mitrani R, Ho C, Sharma S, Dao A, Nelson K, Delarosa K, Rahim U, Mayuram M, Zie JJ, Parikh ND. Direct-active antiviral therapy significantly reduces early HCC recurrence: a multicenter U.S. cohort study. Podium presentation at The Liver Meeting 2018, San Francisco, CA, November 2018.
29. **Murphy CC**, Lee SJC, Geiger AM, Gerber DE, Cox JV, McCallister K, Skinner CS. Community oncologist and practice barriers to clinical trial accrual. Poster presentation at Translational Science 2019, Washington, DC, March 2019.

30. Jetelina KK, Obinwa U, **Murphy C**, Tiro J. Domestic violence screening among breast and cervical cancer oncology clinics at a safety-net hospital. Poster presentation at the 43rd Annual Meeting of the American Society of Preventive Oncology (ASPO), Tampa, FL, March 2019.
31. **Murphy CC**, Lee SJC, Gerber DE, Cox JV, Higashi RT. Patient and provider perspectives on delivery of oral cancer therapies. Poster presentation at the 43rd Annual Meeting of the American Society of Preventive Oncology (ASPO), Tampa, FL, March 2019.
31. Dharwadkar P, Greenan G, Singal AG, **Murphy CC***. Genetic counseling and germline testing among patients with young-onset colorectal cancer at a safety-net hospital. Poster presentation (with distinction) at the 2019 Digestive Disease Week (DDW), San Diego, CA, May 2019.
31. **Murphy CC**, Faqih A, Hewitt BH, Burstein B, Abrams J, Gopal P, Fullington HH, Singal AG. Prevalence of colorectal neoplasia among patients with human immunodeficiency virus. Poster presentation at the 2019 Digestive Disease Week (DDW), San Diego, CA, May 2019.
34. Rich NE, Singal AG, **Murphy CC***. Hepatocellular carcinoma incidence is decreasing among younger adults of all races/ethnicities in the United States. Poster presentation at the 2019 Digestive Disease Week (DDW), San Diego, CA, May 2019.
35. Tavakkoli A, Singal AG, Waljee AK, Elmunzer J, Pruitt SL, Rubenstein JH, Scheiman JM, **Murphy CC***. Racial and geographic disparities in pancreatic cancer incidence and mortality in the United States. Poster presentation (with distinction) at the 2019 Digestive Disease Week (DDW), San Diego, CA, May 2019.
36. **Murphy CC**, Sen A, Sigel BM, Mayo H, Singal AG. Repeat fecal occult blood tests for colorectal cancer screening: systematic review and meta-analysis. Poster presentation at the 2019 Digestive Disease Week (DDW), San Diego, CA, May 2019.
37. **Murphy CC**, Faqih A, Hewitt BH, Burstein B, Abrams J, Gopal P, Fullington HH, Singal AG. Similar prevalence of colorectal neoplasia between patients with and without human immunodeficiency virus. Poster presentation at the 52nd Annual Meeting of the Society for Epidemiologic Research (SER), Minneapolis, MN, June 2019.
38. Rich NE, Yopp AC, Singal AG, **Murphy CC***. Hepatocellular carcinoma incidence is decreasing among young and middle-aged adults in the United States. Podium presentation at the 13th Annual Meeting of the International Liver Cancer Association (ILCA), Chicago, IL, September 2019.
39. Singal AG, McCallister K, Ortiz C, Kramer J, Zhang S, Liu Y, Rich NE, Tiro JA, Lee SC, **Murphy CC**, Hernandez R. Financial burden is common in U.S. patients with cirrhosis and associated with lower HCC surveillance receipt. Podium presentation at The Liver Meeting 2019, Boston, MA, November 2019.
40. **Murphy CC**, Halm EA, Fullington HM, McKey TA, Johnson C, Quirk L, Singal AG. Colorectal cancer screening and yield in a mailed outreach program in a safety-net healthcare system. Poster presentation at the 2020 Digestive Disease Week (DDW), Chicago, IL, May 2020.

41. **Murphy CC**, Cirillo PM, Krigbaum NY, Cohn BA. In utero exposure to 17 α -hydroxyprogesterone caproate may contribute to increasing incidence rates of early-onset cancer. Podium presentation at the 2021 ENDO Meeting, Virtual, March 2021.
42. **Murphy CC**, Cirillo PM, Krigbaum NY, Cohn BA. Gestational growth and risk of young-onset colorectal cancer. Lightning talk at the 45th Annual Meeting of the American Society of Preventive Oncology (ASPO), Virtual, March 2021.
43. **Murphy CC**, Cirillo PM, Krigbaum NY, Cohn BA. In utero exposure to anti-nauseants and risk of young-onset colorectal cancer. Poster presentation at the American Association of Cancer Research (AACR) Annual Meeting 2021, Virtual, April 2021.
43. **Murphy CC**, Cirillo PM, Krigbaum NY, Singal AG, Burstein E, Jones DP, La Hoz R, Cohn BA. In utero exposure to sulfonamide antibiotics and risk of young-onset colorectal cancer. Oral presentation at the 2021 Digestive Disease Week (DDW), Virtual, May 2021.
44. **Murphy CC**, Betts AC. Racial and ethnic disparities in live birth and fetal death among adolescent and young adult women diagnosed with cancer. Oral presentation at the 4th Global Adolescent and Young Adult Cancer Congress, Virtual, December 2021.
45. **Murphy CC**, Betts AC, Allicock A, Shay LA, Preston SM, Lupo PJ, Pruitt SL. Birth outcomes of adolescent and young adult women with cancer in Texas, 1995 – 2016. Oral presentation at the 12th Annual Texas AYA Oncology Conference, Virtual, February 2022.
46. **Murphy CC**, Betts AC, Lupo PJ, Allicock M, Shay LA, Preston SM, Pruitt SL. Risk of fetal death in a population-based sample of 65,000 adolescent and young adult women with a history of cancer. Oral presentation at the 46th Annual Meeting of the American Society of Preventive Oncology (ASPO), Tucson, AZ, March 2022.
47. **Murphy CC**, Cirillo PM, Krigbaum NY, Singal AG, Cohn BA. Infant growth, childhood obesity, and risk of colorectal cancer: a prospective study of 18,000 children. Lecture presentation at Digestive Disease Week (DDW) 2022. San Diego, CA. May 2022.
48. **Murphy CC**, Betts AC, Singal AG, Lupo P, Allicock MA, Shay LA, Preston SM, Pruitt SL. Birth outcomes of young women diagnosed with gastrointestinal cancer. Lecture presentation at Digestive Disease Week (DDW) 2022. San Diego, CA. May 2022.
49. Dharwadkar P, Liu S, Singal AG, **Murphy CC**.* Microsatellite instability and mismatch repair testing in early-onset colorectal cancer. Lecture presentation at Digestive Disease Week (DDW) 2022. San Diego, CA. May 2022.
50. Zaki T, May FP, Liang PS, **Murphy CC**.* Racial and ethnic disparities in early-onset colorectal cancer survival. Lecture presentation at Digestive Disease Week (DDW) 2022. San Diego, CA. May 2022.

Invited Speaking Engagements

1. Invited speaker (with WL Hofstetter), “Esophageal cancer value proposition,” Executive Committee, University of Texas M.D. Anderson Cancer Center, Houston, TX. July 2011.

2. Invited speaker, "Using breast self-awareness messaging in community breast health education outreach," Houston Affiliate of Susan G. Komen for the Cure Grants Committee, Houston, TX. February 2012.
3. Invited speaker (with WL Hofstetter), "What's surgery got to do with it? Exploring the additional benefit of surgery in locally advanced esophageal adenocarcinoma after successful completion of neoadjuvant chemoradiation," Esophageal Tumor Board, University of Texas M.D. Anderson Cancer Center, Houston, TX. March 2012.
4. Panel speaker, "Careers in Epidemiology," presented at the Graduate Program Open House, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC. October 2013.
5. Invited speaker, "Racial disparities in the receipt of adjuvant chemotherapy among stage III colon cancer patients," Gastrointestinal Epidemiology Seminar, University of North Carolina at Chapel Hill, Chapel Hill, NC. October 2014.
6. Invited speaker, "Rising incidence of esophageal adenocarcinoma: an age-period-cohort analysis," Cancer Epidemiology Seminar, University of North Carolina at Chapel Hill, Chapel Hill, NC. November 2014.
7. Invited speaker, "Patterns of repeat and surveillance colonoscopy use," Gastrointestinal Epidemiology Seminar, University of North Carolina at Chapel Hill, Chapel Hill, NC. March 2015.
8. Invited speaker, "Epidemiology and colorectal cancer health services," Gastrointestinal Epidemiology Seminar, University of North Carolina at Chapel Hill, Chapel Hill, NC. November 2015.
9. Invited speaker, "Using epidemiology to improve cancer health services across the colorectal cancer care continuum," Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX. December 2015.
10. Invited speaker, "Using epidemiology to improve cancer health services across the colorectal cancer care continuum," Department of Health Services Research, University of Texas M.D. Anderson Cancer Center, Houston, TX. January 2016.
11. Invited speaker (invited by Dennis Ahnen, MD), "Advancing the science of early-onset CRC: key epidemiologic questions," Early Age Onset Colorectal Cancer Summit, National Colorectal Cancer Roundtable, Bethesda, MD. December 2017.
12. Invited speaker, "Polypharmacy and patterns of prescription medication use among cancer survivors," Translational Science Form, University of Texas Southwestern Medical Center, Dallas, TX. December 2017.
13. Invited speaker, "Tamoxifen and the Road to R01," Clinical Scholars Retreat, University of Texas Southwestern Medical Center, Dallas, TX. March 2018
14. Invited speaker, "Polypharmacy and patterns of prescription medication use among cancer survivors," Department of Pediatrics Grand Rounds, University of Texas Southwestern

Medical Center, Dallas, TX. April 2018.

15. Invited speaker, "Small grants with big impacts: research from five new investigators," 2018 AcademyHealth Annual Research Meeting, Seattle, WA. June 2018.
16. Invited speaker, "Early life exposures and risk of young-onset colorectal cancer," Clinical Scholars Retreat, University of Texas Southwestern Medical Center, Dallas, TX. October 2018.
17. Invited speaker (invited by Dennis Ahnen, MD), "Early-onset colorectal cancer: how can epidemiology help?" Early Age Onset Workshop, Fight Colorectal Cancer (by invitation only), Denver, CO. February 2019.
18. Invited speaker (invited by Shobha Srinivasan, PhD), "Colorectal cancer mortality along the U.S.-Mexico border," 12th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, San Francisco, CA. September 2019.
19. Invited speaker (selected by planning committee), "Early life exposures and risk of young-onset colorectal cancer," New Investigators Workshop, National Cancer Institute, Rockville, MD. November 2019.
20. Invited speaker (invited by Paul Scheet, PhD), "Colorectal cancer: the old, the young, and the underscreened," Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX. December 2019.
21. Panel speaker (invited by Susan Peterson, PhD), "Emerging issues, challenges, and changing epidemiology of EAO-CRC," Early Age Onset Colorectal Cancer Summit, New York, NY. April 2020 (cancelled due to COVID-19).
22. Panel speaker (invited by Andrew Chan, MD, MPH), "Early Onset Colorectal Cancer," Clinical Symposium at the 2020 Digestive Disease Week (DDW), Chicago, IL. May 2020 (cancelled due to COVID-19).
23. Panel speaker (invited by Frank Berger, MD), "Workshop C: Early Onset Colorectal Cancer," 2020 Annual Meeting of the Southeastern Colorectal Cancer Consortium, Louisville, KY. June 2020 (cancelled due to COVID-19).
24. Invited speaker, "Earlier life exposures: maternal obesity and gestational growth," NIH Think Tank on Early-Onset Colorectal Cancer, Virtual. September 2020.
25. Panel speaker (invited by Cathy Eng, MD), "Exploring the Increasing Recognition of Colorectal Cancer in Young Adult Populations," 2020 Gastrointestinal Oncology Conference, International Society of Gastrointestinal Oncology, Virtual. October 2020.
26. Invited speaker, "A life course approach to understand the increasing burden of cancer in young adults." UTHealth School of Public Health, Houston, TX. October 2020.
27. Invited speaker, "Colorectal cancer screening trends in the U.S." Fight Colorectal Cancer, Virtual Webinar. October 2020.
28. Invited speaker (invited by Terrence Barret, MD), "Epidemiology and potential mechanisms

- for the rising tide of early-onset colorectal in the U.S.” Division of Digestive Diseases and Nutrition, University of Kentucky, Virtual. February 2021.
29. Invited speaker, “Risk factors for early-onset colorectal cancer (hint: it’s not bacon).” Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Virtual. February 2021.
 30. Panel speaker (invited by Stephen Gruber, MD), “The big early life story and what it means for colorectal cancer.” Early Age Onset Colorectal Cancer Summit, Virtual. May 2021.
 31. Invited speaker (invited by Jiyoun Ahn, PhD; Robert Coffey, MD; Scott Kopetz, MD, PhD), “Early-onset colorectal cancer: what have we learned and where do we go from here?” 2021 AACR Special Conference on Colorectal Cancer, Virtual. October 2021.
 32. Invited speaker (invited by Jose Perea Garcia, MD, PhD), “Epidemiology of early-onset colorectal cancer.” Collaborative Group of the Americas on Inherited Gastrointestinal Cancer, Virtual. November 2021.
 33. Invited speaker (invited by Paul Schroy, MD), “What is the cause of the rising incidence of early-age-onset colorectal cancer?” 2021 National Colorectal Cancer Roundtable Annual Meeting, Virtual. November 2021.
 34. Invited speaker (invited by Wenyi Wang, PhD), “Early life: an important window of susceptibility for colorectal cancer.” CRC Integromics Group, MD Anderson Cancer Center, Houston, TX. March 2022.
 35. Invited speaker (invited by Elena Stoffel, MD), “Shifting epidemiology of colorectal cancer worldwide.” 2022 Digestive Disease Week (DDW), San Diego, CA. May 2022.
 36. Invited speaker, “An update on the etiology and burden of early-age-onset colorectal cancer.” Fight CRC at the 2022 Digestive Disease Week (DDW), San Diego, CA. May 2022.
 37. Invited speaker (invited by Uri Ladabaum, MD), “Fight CRC: integrating stakeholders with research initiatives in early-onset colorectal cancer.” Colorectal Cancer Screening Committee of the World Endoscopy Organization, San Diego, CA. May 2022.
 38. Invited speaker, “Trends and risk factors for early-onset colorectal cancer.” Sixth Annual Southeastern Colorectal Cancer Consortium Conference, Irving, TX. June 2022.
 39. Invited speaker (invited by Kenneth Tercyak, PhD), “Colorectal cancer in young adults: clues from early life.” Lombardi Comprehensive Cancer Center, Georgetown University, Virtual. July 2022.
 40. Invited speaker (invited by Giulia Martina Cavestro, MD, PhD), “What is the global epidemiology and age cut-off to define early-onset colorectal cancer.” Delphi Initiative Recommendations on Early-onset Colorectal Cancer (DIRECt): The Path to Improve Diagnosis and Clinical Management. San Raffaele Scientific Institute, Milan, Italy. September 2022.
 41. Invited speaker (invited by Lorna Thorpe, PhD), “Pregnancy and cancer in young adults: from risk to outcomes.” Department of Population Health, NYU Langone School of Medicine,

Virtual. December 2022.

Press and Media

1. "Race disparity in colon cancer treatment reemerges in 2010." *Frontline Medical News*. July 6, 2015. <http://www.pm360online.com/race-disparity-in-colon-cancer-treatment-reemerges-in-2010/>.
2. "Differences in colon cancer chemotherapy treatment among African-American and white patients." *Epidemiology News and Reports, UNC Gillings School of Public Health*. July 14, 2015. <http://sph.unc.edu/sph-news/differences-in-colon-cancer-chemotherapy-treatment-among-african-american-and-white-patients/>.
3. "Blacks may be less likely to get chemo for advanced colon cancer." *Reuters Health*. July 16, 2015. <http://www.reuters.com/article/2015/07/16/us-health-racedisparities-colon-cancer-idUSKCN0PQ1MG20150716>.
4. "UNC study finds differences in colon cancer chemo treatment among African-Americans, whites." *Association of Schools and Programs of Public Health (ASPPH)*. July 16, 2015. <http://www.aspph.org/unc-study-finds-differences-in-colon-cancer-chemo-treatment-among-african-americans-whites/>.
5. "Racial, insurance disparities influence chemotherapy receipt for colon cancer." *HemOnc Today*. August 3, 2015. <http://www.healio.com/hematology-oncology/gastrointestinal-cancer/news/online/%7B8d4e445d-5dcf-4418-a3c3-cbada1c79905%7D/racial-insurance-disparities-influence-chemotherapy-receipt-for-colon-cancer>.
6. "1 in 4 U.S. seniors with cancer has had it before." *U.S. News & World Report*. November 22, 2017. <https://health.usnews.com/health-care/articles/2017-11-22/1-in-4-us-seniors-with-cancer-has-had-it-before>.
7. "Researchers question exclusion of people with prior cancer history from clinical trials." *The Medical News*. November 23, 2017. <https://www.news-medical.net/news/20171122/Researchers-question-exclusion-of-people-with-prior-cancer-history-from-clinical-trials.aspx>.
8. "New cancers common in cancer survivors." *OnMedica*. November 23, 2017. <http://www.onmedica.com/newsArticle.aspx?id=8b264804-6dc3-4e3b-a1b4-d58432d96ea3>
9. "Up to one-third of cancer patients have previously had the disease." *United Press International*. November 22, 2017. https://www.upi.com/Health_News/2017/11/22/Up-to-one-third-of-cancer-patients-have-previously-had-the-disease/2021511381619/
10. "1 in 4 U.S. seniors with cancer has had it before." *MedlinePlus*. November 22, 2017. https://medlineplus.gov/news/fullstory_169917.html
11. "Researchers question excluding cancer survivors from clinical trials." *D Magazine*. November 23, 2017. <http://healthcare.dmagazine.com/2017/11/23/researchers-question-excluding-cancer-survivors-from-clinical-trials/>
12. "Study questions exclusion of cancer survivors from trials." *Newswise*. November 22, 2017. <http://www.newswise.com/articles/view/685656/?sc=rsla>

13. "Prevalence of secondary cancers underscores need for trial inclusion." HemOnc Today (Healio). November 22, 2017. <https://www.healio.com/hematology-oncology/prostate-cancer/news/in-the-journals/%7B48ce8455-5fa1-411f-8a16-59d27cb0c697%7D/prevalence-of-secondary-cancers-underscores-need-for-trial-inclusion>.
14. "Second cancers common in survivors, especially older adults." Medscape. November 22, 2017. <https://www.medscape.com/viewarticle/889062>.
15. "1 in 4 U.S. seniors with cancer has had it before." WebMD. November 24, 2017. <https://www.webmd.com/cancer/news/20171122/1-in-4-us-seniors-with-cancer-has-had-it-before>.
16. "High incidence of prior cancer in patients newly diagnosed with cancer." medwireNews. November 27, 2017. <https://www.medwirenews.com/oncology/high-incidence-of-prior-cancer-in-patients-newly-diagnosed-with-/15257098>.
17. "When cancer strikes twice." New York Times. December 26, 2017. https://www.nytimes.com/2017/12/25/well/when-cancer-strikes-twice.html?_r=0.
18. "Cancer survivors more likely to be prescribed multiple medications." HemOnc Today. May 8, 2018. <https://www.healio.com/hematology-oncology/practice-management/news/in-the-journals/%7B8aa6a277-a322-4905-91f6-c1fd4776b45f%7D/cancer-survivors-more-likely-to-be-prescribed-multiple-medications>.
19. "Young-onset CRC uptick driven by more rectal cancers among whites." Healio Gastroenterology. December 7, 2018. <https://www.healio.com/gastroenterology/oncology/news/online/%7Bb2aaaddb-445e-46d8-86e3-528940b85cae%7D/young-onset-crc-uptick-driven-by-more-rectal-cancers-among-whites>
20. "Drug used during pregnancy may increase cancer risk in mother's adult children." Newswise. March 17, 2021. <https://www.newswise.com/articles/drug-used-during-pregnancy-may-increase-cancer-risk-in-mother-s-adult-children>
21. "Drug used to prevent miscarriages may increase cancer risk of grown children." Philly Voice. March 23, 2021. <https://www.phillyvoice.com/makena-cancer-risk-ohpc-preterm-birth-drug/>
22. "Drug used to prevent miscarriages may be upping cancer rates decades later." U.S. News & World Report. March 24, 2021. <https://www.usnews.com/news/health-news/articles/2021-03-24/drug-used-to-prevent-miscarriages-may-be-upping-cancer-rates-decades-later>
23. "Blacks, Hispanics, impoverished people have worse survival rates among teens, adults under 40 with cancer." Newswise. April 22, 2021. <https://www.newswise.com/articles/blacks-hispanics-impoverished-have-worse-survival-rates-among-teens-adults-under-40-with-cancer>
24. "Race, neighborhood poverty, insurance associated with higher mortality in people under 40 with cancer." News-Medical.Net. April 22, 2021. <https://www.news-medical.net/news/20210422/Race-neighborhood-poverty-insurance-associated-with-higher-mortality-in-people-under-40-with-cancer.aspx>
25. "When cancer strikes those under 40, race matters." U.S. News & World Report. April 28, 2021. <https://www.usnews.com/news/health-news/articles/2021-04-28/when-cancer-strikes-those->

under-40-race-matters

26. "For young Texans, race is a stronger predictor of cancer survival than insurance status." Texas Standard. April 28, 2021. <https://www.texasstandard.org/stories/for-young-texans-race-is-a-stronger-predictor-of-cancer-survival-than-insurance-status/>
27. "Mom's obesity during pregnancy linked to colon cancer in offspring." MedPage Today. August 23, 2021. <https://www.medpagetoday.com/obgyn/pregnancy/94179>
28. "People whose mothers were overweight at higher risk of bowel cancer, study suggests." The Guardian. August 23, 2021. <https://www.theguardian.com/society/2021/aug/23/people-whose-mothers-were-overweight-at-higher-risk-of-bowel-cancer-study-suggests>
29. "Maternal obesity, weight gain increase risk for CRC among adult offspring." Healio Gastroenterology. August 24, 2021. <https://www.healio.com/news/gastroenterology/20210824/maternal-obesity-weight-gain-increase-risk-for-crc-among-adult-offspring>
30. "Study examines link between in utero events and risk of colorectal cancer in adult offspring." The ASCO Post. September 1, 2021. <https://ascopost.com/news/september-2021/study-examines-link-between-in-utero-events-and-risk-of-colorectal-cancer-in-adult-offspring/>
31. "Maternal obesity may up CRC risk in adult offspring." Cancer Therapy Advisor. August 30, 2021. <https://www.cancertherapyadvisor.com/home/cancer-topics/gastrointestinal-cancers/maternal-obesity-may-up-crc-risk-in-adult-offspring/>
32. "Maternal obesity linked to higher risk of colorectal cancer in adult offspring." American Association for the Advancement of Science (AAAS). August 24, 2021. <https://www.eurekalert.org/news-releases/926656>
33. "Maternal obesity linked to higher risk of colorectal cancer in adult offspring." Newswise. August 26, 2021. <https://www.newswise.com/articles/maternal-obesity-during-pregnancy-linked-to-higher-risk-of-colorectal-cancer-in-adult-offspring>
34. "Maternal obesity during pregnancy may heighten the risk of colorectal cancer in adult offspring." News Medical Life Sciences. August 27, 2021. <https://www.news-medical.net/news/20210827/Maternal-obesity-during-pregnancy-may-heighten-the-risk-of-colorectal-cancer-in-adult-offspring.aspx>
35. "Maternal obesity tied to increased risk of colorectal cancer in offspring." Reuters/Medscape. August 26, 2021. <https://www.medscape.com/viewarticle/957263?src=>
36. "Maternal health may play a big role in who gets colorectal cancer." KPRC-TV Houston. September 10, 2021. <https://www.click2houston.com/news/local/2021/09/11/maternal-health-may-play-a-big-role-in-who-gets-colorectal-cancer/>
37. "Study shows dramatic decline in effectiveness of all three COVID-19 vaccines over time." Los Angeles Times. November 4, 2021. <https://www.latimes.com/science/story/2021-11-04/study-shows-dramatic-decline-in-effectiveness-of-covid-19-vaccines>
38. "Pfizer-BioNTech expected to seek authorization for coronavirus booster for people 18 and older." Washington Post. November 9, 2021.

<https://www.washingtonpost.com/health/2021/11/08/pfizer-biontech-coronavirus-booster-authorization-18-and-older/>

39. "Drug used to prevent miscarriage increases risk of cancer in offspring. Science Daily. November 9, 2021. <https://www.sciencedaily.com/releases/2021/11/211109120334.htm>
40. "Colorectal cancer rates rising in people aged 50 to 54 years. Medscape. November 11, 2021. <https://www.medscape.com/viewarticle/962769>
41. "Drug used to prevent miscarriage may raise lifetime cancer risk in offspring. U.S. News & World Report. November 15, 2021. <https://www.usnews.com/news/health-news/articles/2021-11-15/drug-used-to-prevent-miscarriage-may-raise-lifetime-cancer-risk-in-offspring>
42. "Preterm birth drug tied to cancer risk in those exposed in utero. Medpage Today. November 16, 2021. <https://www.medpagetoday.com/obgyn/pregnancy/95623>
43. "The colon cancer conundrum." Scientific American. December 1, 2021; S12. <https://www.scientificamerican.com/article/the-colon-cancer-conundrum/>
44. "A drug for pregnant women doesn't work, according to the FDA. A company is selling it anyway." Los Angeles Times. February 17, 2022. <https://www.latimes.com/business/story/2022-02-17/makena-covis-premature-birth-pregnant-womens-health>
45. "FDA should pull ineffective pregnancy drug Makena until we know it works." Los Angeles Times. February 24, 2022. <https://www.latimes.com/opinion/story/2022-02-24/editorial-does-this-drug-work-stop-selling-it-until-we-know>
46. "Organized CRC screening programs crucial for increasing adherence." Gastroenterology & Endoscopy News. July 25, 2022. <https://www.gastroendonews.com/Functional-GI-Disorders/Article/07-22/CRC-Screening-Colorectal-Cancer-Adherence/67419>
47. "Colorectal cancer screening prevalence remains low among younger adults." HemOnc Today. June 29, 2022. <https://www.healio.com/news/hematology-oncology/20220629/colorectal-cancer-screening-prevalence-remains-low-among-younger-adults>

Professional Activities

Grant Review Panels

- | | |
|------|--|
| 2017 | Ad-hoc Reviewer, Emerging Investigator Awards for Health, Health Research Board (Ireland) |
| 2021 | Ad-hoc Reviewer, Cancer Health Equity Research Centers at Minority-Serving Institutions, American Cancer Society |
| 2022 | Ad-hoc Reviewer, Women's Health Research at Yale, Yale University School of Medicine |
| 2022 | Ad-hoc Reviewer, Cancer Health Equity Research Centers at Minority-Serving Institutions, American Cancer Society |

Service to Professional Journals

Member, Editorial Board, Gastroenterology

Ad-hoc Reviewer for:

Cancer
Pharmacoepidemiology and Drug Safety
Cancer Epidemiology Biomarkers & Prevention
Journal of the National Cancer Institute
Breast Cancer Research and Treatment
Journal of Clinical Oncology
British Journal of Cancer
BMC Cancer
Medical Care
Cancer Causes & Control
Cancer Medicine
Annals of Epidemiology
International Journal of Cancer
Gastroenterology
Clinical Gastroenterology and Hepatology
American Journal of Preventive Medicine
Gut
Epidemiology

Relevant Coursework and Skills

Coursework

Fundamentals in Epidemiology
Theory and Quantitative Methods in Epidemiology
Epidemiologic Data Analysis
Logic and Probability in Epidemiology
Epidemiologic Analysis of Binary Data
Advanced Methods in Epidemiology
Epidemiologic Research Using Healthcare Databases
Proposal Development for Epidemiologic Research
Cancer Epidemiology and Pathogenesis
Cancer Survivorship and Outcomes
Cancer Prevention and Control
Program Planning and Evaluation
Health Promotion Theory and Methods
Advanced Methods for Planning Health Promotion Programs
Principles of Experimental Data Analysis
Categorical Data Analysis
Latent Variable Analysis and Structural Equation Modeling
Age-Period-Cohort Analysis
Systematic Review and Meta-Analysis
Social and Economic Determinants of Health
Quality of Care

Responsible Conduct of Research
Grant Writing & Funding Strategies

Software Skills: SAS (preferred), Stata, Mplus, Sudaan

Datasets: NHANES, NHIS, BRFSS, MEPS, SEER, SEER-Medicare, MarketScan (Truven Health), POC